Epidemiology of confirmed measles virus cases, surveillance, incidence, and associated factors in Eritrea: 18-year retrospective analysis

Epidemiology of confirmed measles virus cases, surveillance, incidence, and associated factors in Eritrea: 18-year retrospective analysis | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Epidemiology of confirmed measles virus cases, surveillance, incidence, and associated factors in Eritrea: 18-year retrospective analysis Samuel Tekle Mengistu, Oliver Okocht Achila, Asmerom Tesfagiorgis Tewelde, and 10 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-2905015/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Understanding the incidence of laboratory-confirmed measles virus (MV) cases, related factors, and spatial inequalities in testing and surveillance is crucial to proving evidence-based decisions in measles prevention and control programs. In this analysis, our aim was to evaluate these factors in Eritrea. Methods Reviewed and analyzed a disease surveillance database from 2002 to 2020, used descriptive statistics and logistic regression, and calculated spatial variability and distribution of confirmed cases using ArcGIS Pro version 3.0.1 with a significance level of 5%. Results The median age (IQR) was 7 years (4–14 years) and the minimum-maximum age was 1 month – 97 years. In total, 9,111 suspected cases, 2,767 (1,431 (51.7%) females vs 1,336 (48.3%) males) were serologically tested. Among the 608 (21.9%) laboratory-confirmed cases, 534 (87.8%) were unvaccinated and 53 (9.92%) were 30 years presenting the highest rates, 69.9/100,000. The probability of test positivity was associated with an increasing age at the beginning of the rash (5–9 years: OR = 0.7, 95%CI: 0.5–0.9, p value = 0.02) (10–14 years: OR = 1.6, 95%CI: 1.1–2.2, p value = 0.005) (15–29 years: OR = 7, 95%CI: 5.3–9.2, p-value = 30: OR = 16.7, 95%CI: 11.7–24, p-value < 0.001); Address (Anseba: OR = 2.3, 95%CI: 1.7–3.1, p-value < 0.001) (Debub: OR = 2.7, 95%CI: 1.9–3.9, p-value < 0.001) (Gash-Barka: OR = 15.4, 95%CI: 10.9–21.7, p-value < 0.001) (Northern Red Sea: OR = 11.8, 95%CI: 8.5–16.2, p-value < 0.001) (Southern Red Sea: OR = 14.4, 95% CI: 8.2–25.2, p-value < 0.001); Health facility (Health centre: OR = 2.5, 95%CI: 1.9–3.4, p-value < 0.001) (Hospital: OR = 6.8, 95%CI: 5.1–9.1, p-value < 0.001); Vaccination status (Unvaccinated: OR = 14.7, 95%CI: 11.4–19.1, p-value < 0.001); and year of onset of rash (2015: OR = 1.4, 95% CI: 1.1–1.7, p-value < 0.001). Interestingly, uptake of the measles vaccine (MCV) coverage was associated with a similar complement of factors. Conclusion The study concludes that efforts to eliminate measles in Eritrea are hindered by disparities in vaccine coverage and surveillance, and low vaccination rates in neighboring countries. The paper suggests that regional microplanning could be an effective strategy to improve surveillance and management in hard-to-reach regions. Epidemiology General Microbiology Virology Measles Surveillance Vaccination Epidemiology Spatial inequality Figures Figure 1 Figure 2 Introduction Measles virus (MV), a member of the genus Morbilivirus , family Paramyxoviridae , is an antigenically monotypic, enveloped, single-stranded (SS) virus with a non-segmented negative (-) sense RNA genome (1). Like other Morbiliviruses , MV is highly contagious (basic reproductive number (R 0 = 10–18) and can cause multiple complications (1). Following exposure by respiratory route or contact with respiratory droplets, up to 90% of susceptible people can develop systemic infection within 10–14 days (up to 3 weeks in adults) (2). The 1 to 3 day prodromal phase is hallmarked by fever, malaise, and the three C (cough, coryza, and conjunctivitis) (3). A common finding at this stage is Koplik’s spot and an erythematous maculopapular rash. Although MV infection is self-limiting, common sequelae include transient immunosuppression, diarrhea, otitis media, laryngotracheobrochitis, pneumonia (accounts for 90% of measles mortality), and post-viral encephalitis. On rare occasions, it can lead to subacute sclerosing panencephalitis, a potentially fatal central nervous system (CNS) complications (1). Before the introduction of the measles vaccine in the 1960s, MV epidemics occurred periodically (every 2 to 3 years), with approximately 2.6 million mortalities annually (3). However, the scale-up of vaccine coverage, particularly in low- and middle-income countries (LMICs) in the 1990s triggered a significant decline in incidence, morbidity, and mortalities (4). Based on measles case-based surveillance data in Africa, the number of cases decreased from 520,102 cases in 2000 to 98,621 cases in 2015 translating into a corresponding incidence decline of 841 per 1000,000 to 100 per 1000,000 in the same period (3). The report also concluded that measles vaccination [measles-containing vaccine 1 (MCV1), measles-containing vaccine 2 (MCV 2) and supplemental immunization activities (SIAs)] prevented 23.2 million deaths from 2000–2018 (3). Importantly, declines in mortality have paralleled steep declines in MV-associated disability-adjusted life-years (DALYs). From 1990 to 2019, the DALY rates decreased from 2.7 (Uncertainty interval (UI):0.9–5.6) to 0.3 (UI: 0.1–0.6), translating into a percentage change of -89.8%(-92.3%-86.8%) (5). However, measles still account for a significant number of deaths globally (> 140,000 persons in 2018, mostly children < 5 years) (6). By most accounts, the remarkable decline in the burden of measles in Sub-Saharan Africa (SSA) is closely intertwined with multiple policy prescriptions of the World Health Organisation (WHO) policy prescription. In 2008, following the earlier standards set by the 2006–2015 Global Immunisation Vision and Strategy; the WHO adopted its four-point pre-elimination plan for the African Region (AFR) (7). These included: 1) > 98% reduction in measles mortality with the year 2000 as the baseline, 2) annual incidence of measles incidence 90% MCV1 coverage nationally > 80% coverage in districts, and 4) > 95% SIA in all districts. Specific surveillance performance objectives were also embedded in the document. In 2011, these goals were adopted by the WHO AFR 2020 measles elimination plan, and subsequently incorporated into its regional immunization strategic plan (7). In Eritrea, the Expanded Programme on Immunisation (EPI) began in 1980 (pre-independence era). The original EPI included the provision of the first dose of measles-containing vaccine (MCV1) at 9 months of age. However, the coverage of MCV1 in this period was very low, 34% (8). In 2003, the country implemented SIAs. This was followed by the implementation of case-based surveillance in 2005, and MCV2 in 2012. According to the WHO-AFR goals, and its second national Strategic Development Plan (HSSDP-II) (2017–2021); Eritrea adopted the > 95% (MCV1)-90% (MVC2) as a primary part of its national multiyear plan for immunization. Currently, the WHO and United Nations Children’s Fund (WHO/UNICEF) score card on vaccination estimates suggest that Eritrea has consistently reported > 95% MCV1 since 2003 and > 88% MCV2 coverage since 2015 (8). Although the adoption of these policies was broadly successful; The MCV2 and SIAs targets, surveillance performance targets, and incidence rates < 5 per 1,000,000 cases nationwide were not met (9). In other settings across WHO-AFR regions, underperformance in these indicators has been associated with poor access to community-linked immunization services; inadequate infrastructure for laboratory-supported case-based surveillance, poor quality of data, and reduction in vaccine effectiveness, among others (9). Importantly, others have opined that national WHO-UNICEF estimates (vaccination or measles burden) can mask within-country disparities, and context-specific social and economic drivers of measles infections. For this reason, clusters of unvaccinated or under-vaccinated individuals are known to exist even in countries with relatively high MCV coverage. To remedy this situation, renewed research effort is required, particularly in hard-to-reach communities, is required. Such investigations should also focus on spatiotemporal heterogeneity in measles incidence, testing and MCV coverage. Equally vital is the need to understand demographic correlates of measles infection at the local level. In this analysis, our objective was to evaluate the incidence and spatiotemporal distribution of measles in Eritrea. Furthermore, an evaluation of the factors associated with measles vaccination and IgM positive (+) febrile rash was attempted. Methods Study design, population, and settings We conducted a retrospective analysis of data collected in Eritrea from 2002–2020. Eritrea is a country located in the upper part of the Horn of Africa. The country is bounded to the east by the Red Sea; to the North and west by Sudan; to the South by Ethiopia and to the South East by Djibouti. It has a surface area of ~ 124,000 Km 2 and a total population of 3,905,066, including ~ 117 152 surviving infants as of 2022. According to the Inter-Agency Group of the United Nations for Child Mortality Estimation, the mortality rate, and infant mortality rate in 2020 were 38 per 1,000 live births and 18 per 1,000 live births, respectively(10). Administratively, the country is divided into six Zobas (regions): Maekel (central region), Gash Barka, Anseba, Debub, Debubawi Keih Bahri (DKB) (Southern Red Sea) and Semienawi Keih Bahri (SKB) (Northern Red Sea). The regions are further subdivided into 58 sub-zones, 699 administrative areas, and 2564 villages. Healthcare is provided, almost exclusively, by the Eritrea Ministry of Health through a three-tier system, namely primary care level (serves ~ 500–2000 people), secondary care level (serves ~ 5,000–10 000) and tertiary care level (serves ~ 50,000–100 000). Using the reaching every district approach, the country’s EPI program, which is housed as a unit within the Department of Public Health; delivers immunization services, 6 days per week, through 302 (85%) health facilities and 450 outreach sites (8). In addition, country implements Periodic Intensified Routine Immunization (PIRI) services, every quarter for nomadic and semi-nomadic population groups and people living in 16 hard-to-reach districts. As of December 2021, the national immunization target includes antigens against 12 vaccine preventable diseases. Overall, data from vaccination cards and mother’s reports suggest that in 2020, 99.4%, 98.9%, 98.8% and 96.9% received required doses of Bacillus Calmette Guérin (BCG) vaccine, oral polio vaccine (OPV), PENTA-3 (vaccine for Hepatitis B virus (HBV), Diptheria-Pertussis-Tetanus (DPT), Haemophilus influenza type b) and measles-mumps-rubella (MMR) - MCV (MCV1 at 9 months and MCV2 at 15 months), respectively. Data Source and Study Variables In Eritrea, the national serological laboratory conducts measles case-based surveillance to confirm measles cases is undertaken by the national serological laboratory. The surveillance protocols used by the measles serological laboratory are based on WHO-AFR standards (11). It includes individual case investigation and blood specimen collection for laboratory testing (9) in national or regional reference laboratories. At present, molecular techniques (real-time polymerase chain reaction (RT-PCR) and sequence analysis) or cell culture are not available in the national laboratory. In general, the data used in this analysis were from the primarily obtained integrated disease surveillance and response database (IDSR). The database contains information on the number of measles tests conducted per year at the National Hospital Laboratory (the only testing center in Eritrea). The data used for age standardization were obtained from the Eritrea Statistics Office. The variables considered in this analysis included total notified cases, number of notified cases which were tested, positive immunoglobulin M (IgM) (+), Ig M-/ Intermediate, and epidemiological linked cases (EPI-linked), and final outcome of MCV infection. Additional information included patient sex, age at onset of rash, address, health facility, vaccination status, last vaccination, and date of the onset of rash. Data Collection Procedures and data quality In this study, data (spanning the period from 2002 to 2020) was abstracted IDSR using a form designed for this purpose. The variables captured included age at the beginning of the rash, years, address (region / zone), facility level, vaccination status, and last vaccination. To ensure compliance with specific ethical requirements, all participant data were de-identified. At this stage, the data were managed using CSPro software (version 7.0). Operational Definitions A suspected measles case was defined according to the WHO-AFR Measles and Rubella Surveillance Guideline [WHO-AFR] – persons with a generalized maculopapular rash, fever, plus one or more of the following: coryza, cough, conjunctivitis, OR any person in whom a clinician suspects measles (12). A confirmed measles case was defined as the presence of measles-specific IgM antibodies (IgM + ) of a titer that exceeded the thresholds indicative of infection in people without evidence of vaccination in the last 30 days (13). Epidemiologically linked case refers to a suspected case that has been linked (in person, place, and time) to a laboratory confirmed case (13). A non-measles case was defined as any notified case/suspected case that was measles-specific IgM (-) after testing as per established protocols. The status of measles vaccination was categorized into vaccination (at least MCV1), non-vaccination, and unknown status. Main results of the study The outcome variables included the crude incidence rate (CIR), age adjusted incidence rates, and age-specific measles IgM positivity. Additional outcomes included factors associated with measles-specific IgM positive febrile rash and vaccination. The spatial distribution of measles tests and positive cases from 2002–2020 across Eritrean sub-zones was also evaluated. Statistical Analyses Data was analysed using IBM® SPSS® Statistics for Windows, version 26 (IBM Corp., Armonk, N.Y., USA). Crude incidence rates (CIR), age standardised rates (ASR), and specific measures of central tendency, medians (± Interquartile ranges (IQR)) and means (± standard deviations (SD) were computed where applicable. The CIR was calculated by diving the total number of confirmed cases (by laboratory serology) per year or age category as the number of the total population. The numbers used in these denominators were obtained from the Eritrea National Statistics Office (14). To test for differences in medians or frequencies between groups, Kruskal-Wallis, Mann-whitney U, or Chi-squire statistics ( 2) were used. Subsequently, binary logistic regression models were fitted to identify the predictors of measles test positivity or vaccine uptake of vaccine in the population. The results were finally presented in tables, graphs, and figures. Furthermore, the spatial variability in the tests and the distribution of confirmed cases during the study period was calculated using ArcGIS version 10.1. Ethical Considerations The study was carried out according to the Declaration of Helsinki and was approved by Ethical Committee of the Eritrean Ministry of Health (EMH). Written consent was not obtained from the patients. Instead, the data were identified and all ethical and professional considerations undergirding confidentiality/or others protections of patient information were rigorously implemented. Results From 2002 to 2020, ~ 9,111 cases of febrile rash notifications were reported in Eritrea. However, of 2,767 (30.4%) cases were tested; MV IgM was 607 (21.9%) and 82 (3% of the tested) were epidemiologically linked. Mean (± SD), 10.5 months (± 10.4 months) with a minimum age – maximum age of the cases was 1 month and 97 months, respectively. The overall CIR of MV was 14 per 100,000. Overall, 17 (3% of the total measles) cases died due to measles and/or its complications. This translates into a reported MV-related death rate of 24.6 per 1,000. See Table 1 . Table 1 Distribution of measles serologic test results across years from 2002–2020 in Eritrea Year Total cases notified Tested n(%) IgM+ Ig M-/ Intermediate Epi link Crude rate per 100,000 Measles death MDR/1000 2002 85 79 (93) 23 56 0 0.8841 0 0 2003 363 99 (27) 48 51 21 1.7969 1 14.5 2004 48 40 (83) 9 31 8 0.3417 0 0 2005 95 89 (94) 14 75 6 0.5166 0 0 2006 134 128(96) 4 125 0 0.1076 4 1000 2007 58 58(100) 0 58 0 0.03486 0 0 2008 65 64(98) 0 64 0 0.03389 0 0 2009 73 52(71) 3 49 0 0.0988 0 0 2010 171 171(100) 5 166 0 0.1601 0 0 2011 147 147(100) 14 133 0 0.4357 0 0 2012 682 305(45) 119 186 40 3.6 1 6.2 2013 621 150(24) 47 103 0 1.382 4 85 2014 127 114(90) 1 113 7 0.0285 0 0 2015 468 202(43) 91 111 0 2.528 6 65.9 2016 726 364(50) 79 285 0 2.1378 0 0 2017 3,150 196(6.2) 60 136 0 1.5794 1 16.6 2018 1,023 176(17) 70 106 0 1.7925 0 0 2019 545 191(35) 8 183 0 0.1993 0 0 2020 620 142(23) 13 129 0 0.3151 0 0 Total 9,111 2,767(30.4) 607 2,160 82 14 17 24.6 Definition: Attack rates; Number of measles/ total number of patients tested. Abbreviations: MDR; measles death rate Crude incidence rate, age adjusted incidence rates, and age-specific measles IgM positivity In this analysis, a higher CIR and age-specific incidence of measles was observed in adults: ==30 years, 69.9 per 100 tested. The CIR (ASR) during the study period: ==30 years, 4.2 per 100 000 (76.79) per 100 000). Furthermore, there was a pan age group increase in measles incidents from 2015 to 2018. See Table 2. Table 2 Crude incidence rate per 100,000, age adjusted incidence rates (ASR) per 1,000,000 and age specific positivity among 100 individuals the tested for measles in Eritrea, 2002–2020 CIR (ASR) Age specific positivity rate per 100 tested Year ==30 ==30 Total 2002 0.2 (.78) 0.2(.77) 0.04(.76) 0.36(2.18) 0.08(4.36) 25 15.6 100 90 66.7 33.3 2003 0.12(.59) 0.47(1.5) 0.63(1.5) 0.59(4.42) - 30 70.6 69.6 83.3 - 66.7 2004 0.04(.3) 0.11(.3) 0.08(.29) 0.08(.84) 0.04(1.68) 7.7 18.8 33.3 100 100 23.7 2005 0.07(.46) 0.22(.45) - 0.15(1.27) 0.07(2.54) 7.4 15.4 - 66.7 66.7 15.7 2006 - 0.07(.09) 0.04(.09) - - - 3.4 4.2 - - 2.3 2007 - - - - - - - - - - - 2008 - - - - - - - - - - - 2009 - 0.03(.09) - 0.03(.24) 0.03(.49) - 3.7 - 50 100 5.8 2010 - - 0.03(.14) 0.1(.39) 0.03(.79) - - 6.7 33.3 100 2.9 2011 0.03(.39) 0.09(.38) 0.03(.37) 0.19(1) 0.09(2.15) 2.4 5.2 4.5 31.6 50 9.5 2012 0.27(3.19) 0.12(3.13) 0.06(3.1) 2(8.86) 1.15(17.7) 12.7 7.1 9.5 61.7 78 39.3 2013 0.06(1.22) 0.06(1.2) 0.15(1.19) 0.76(3.4) 0.35(6.81) 5.4 5.4 33.3 57.8 84.6 31.3 2014 0.03(.03) - - - - 2 - - - - - 2015 0.14(2.24) 0.28(2.2) 0.17(2.17) 0.94(6.22) 1(12.45) 16.7 20.4 25 61.8 83.7 45.3 2016 0.35(1.89) 0.38(1.86) 0.08(1.84) 0.46(5.26) 0.87(10.5) 12.9 10.5 7.3 35.4 78 21.7 2017 0.63(1.4) 0.21(1.37) 0.37(1.36) 0.21(3.89) 0.13(7.78) 36.4 15.4 29.8 38.1 55.6 30.3 2018 0.67(1.59) 0.18(1.56) 0.26(1.54) 0.41(4.41) 0.26(8.83) 44.1 22.6 35.7 43.2 50 39.4 2019 0.1(.18) 0.02(.17) - 0.05(.49) - 4.4 1.6 - 18.2 - 3.7 2020 0.1(.28) 0.02(.27) 0.02(.27) 0.07(.78) 0.07(1.55) 5.8 2 5 37.5 42.9 7.8 Total 3(14.54) 2.5 (15.34) 2 (14.6) 6.4 (43.65) 4.2 (77.69) 11.7 8.6 17.4 49.8 69.9 21.5 Definitions: Attack rates age specified = number of measles cases/number of people tested positive in that age group Factors associated with measles IgM positive febrile rash Among the measles positive individuals’ females account for 55% (n=334). The median age of positive individuals is higher than that of negative individuals (18 [7-29] vs 6 [3-10] years, Kruskal-Wallis test, p<0.001). The highest proportion of positives lie in the age group 15-29 years: 212 (35.1%) followed by more than 30 years 146 (24.2%), less than 4 years 102 (16.9%), 5-9 years 79 (13.1%), and 10-14 years 65 (10.8%), chi-square test p<0.001. Among the countries zones, a higher positivity was observed in the regions of NRS 145 (23.8%) and Anseba 142 (23.4%), chi-square p< 0.001. No apparent differences in the number of incidence cases by sex were observed (Table 1). Higher odds of MCV positivity were observed in Gash-Barka (OR=15.4(10.9-21.7), p<0.001), Southern Red Sea (OR=14.4 (8.2-25.2), p<0.001), Northern Red Sea (OR=11.8 (8.5-16.2), p<0.001), Debub (OR=2.7 (1.9-3.9), p<0.001) and Anseba (OR=2.3 (1.7-3.1), p<0.001) when compared to Maekel region. Hospitals’ samples showed higher of odds of MCV positivity (224, 45.3%) when compared to health centers or stations, (OR=6.8 p<0.001, hospital vs health station). Higher odds of test positivity were also observed in unvaccinated individuals (OR=14.7 (11.4-19.1), p<0.001). See Table 3. Table 3 Factors associated with measles status in Eritrea, 2002–2020 Characteristics Measles status p -value ( χ 2) OR (95%CI) p -value Positive (%) Negative (%) Intermediate N (%) Gender Male 267 (44.4) 990 (48.3) 50 (56.3) 0.06 (5.5) 1( Ref. ) Female 334 (55.6) 1058 (51.7) 38 (43.7) 1.18 (.9-1.42) 0.06 Age at onset of rash, median (IQR) 18 (7–29) 6 (3–10) 11 (5–18) < 0.001 a =<4 102(16.9) 731 (35.4) 18 (20.7) < 0.001 (645.7) 1( Ref. ) 5–9 79 (13.1) 805 (39) 18 (20.7) 0.7 (0.5–0.9) 0.02 10–14 65 (10.8) 274 (13.3) 21 (24.1) 1.6 (1.1–2.2) 0.005 15–29 212 (35.1) 203 (9.8) 19 (21.8) 7 (5.3–9.2) =30 146 (24.2) 53 (2.6) 11 (12.6) 16.7 (11.7–24) < .001 Address Maekel 91 (15) 962 (46.4) 33 (37.5) < 0.001 (501.2) 1( Ref. ) Anseba 142 (23.4) 637 (30.8) 24 (27.3) 2.3 (1.7–3.1) < .001 Debub 64 (10.5) 239 (11.5) 13 (14.8) 2.7 (1.9–3.9) < .001 Gash-Barka 133 (21.9) 90 (4.3) 4 (4.5) 15.4 (10.9–21.7) < .001 NRS 145 (23.8) 120 (5.8) 13 (14.8) 11.8 (8.5–16.2) < .001 SRS 33 (5.4) 24 (1.2) 1 (1.1) 14.4 (8.2–25.2) < .001 Health facility Health station 90 (18.2) 624 (47.2) 22 (37.3) < 0.001 (198) 1( Ref. ) Health center 180 (36.4) 478 (36.1) 23 (39) 2.5 (1.9–3.4) < .001 Hospital 224 (45.3) 221 (16.7) 14 (23.7) 6.8 (5.1–9.1) < .001 Vaccination status At least one dose 74 (12.2) 1380 (66.6) 46 (52.3) < 0.001 (604.7) 1( Ref. ) Unvaccinated 534 (87.8) 654 (31.6) 42 (47.7) 14.7 (11.4–19.1) < .001 Unknown - 38 (1.8) - Last vaccination 2009 (2004–2014) 2011 (2004–2015) 2006 (2003–2013) =2010 40 (54.1) 635 (46) 15 (32.6) 1.4 (0.8–2.2) 0.15 Year of onset of rash 2012 (2010–2017) 2015 (2012–2016) 2016 (2007–2018) 0.07 a =<2014 287 (75.1) 1175 (91.9) 36 (82.9) =2015 91 (24.1) 104 (8.1) 7 (17.1) 1.4 (1.1–1.7) < .001 Abbreviations: NRS: Northern Red Sea; SRS: Southern Red Sea; IQR: Interquartile Range. Factors associated with measles vaccination In the bivariate analysis, we demonstrated that unvaccinated individuals were older with a median age (IQR) of 9 (IQR: 1-25) years vs the vaccinated 3 (IQR: 3-8) years, Mann-Whitney U test p<0.001. Additionally, vaccination uptake was associated with age at the time of rash appearance, address, type of health facility, and year of onset of rash. Consequently, 276 (22.5%), 235 (19.26%), 150 (12.3%), 365 (29.8%) and 198(97.1%) of patients ==30 years were not vaccinated. In the respective administrative zones, namely: Maekel, Anseba, Debub, Gash-Barka, NRS, and SRS; 270 (25.62%), 332 (41.4%), 153 (48.57%), 189 (84.00%), 232 (84.06%), 55 (94.83%) of patients presenting morbiliform rash were unvaccinated. Additionally, 228 (30.9%), 304 (44.7%) and 315 (66.63%) of patients with rashes in health stations, health centers and hospitals were not vaccined. Last but not least, ==2015 analysis of = 2014 vs> = 2015 of the vaccination status of individuals who presented a rash indicated that 720 (49.38%) and 510 (40.13%) were not vaccined. In the multivariate analysis, a high odd of being unvaccinated was associated with the age at onset of rash (1.11 (95% CI 1.10-1.13), p value<0.001); administrative zone (SRS: aOR=23(95% CI: 4.6-114), p value<0.001) (NRS: aOR=7.6 (95% CI: 4.6-12.7) (Anseba: aOR=2.4(95% CI: 1.8-3.2) (Debub: aOR=1.8 (95% CI: 1.2-2.6); and health facility (Health centre: 0.95 (95% CI: 0.72-1.3) (hospital: 5.1 (955 CI: 3.6 – 7.2), p value< 0.001). Lastly, there was a notable association between year of rash onset and vaccination status (0.94 (95% CI: 0.90-0.99), p-value = 0.02). In other words, for each increase in year, there was a 6% increase in vaccination status of individuals with febrile rash (p=0.02). Table 4 Factors associated with measles vaccination among individuals with rash in Eritrea, 2002-2020 Characteristics Vaccination status p -value ( χ 2 ) OR (95%CI) p -value aOR (95%CI) p-value At least once (%) Unvaccinated (%) Gender Male 701 (54.6) 583 (45.4) 0.8 (0.06) 1( Ref. ) Female 780 (55.1) 636 (44.9) 0.9 (0.8-1.1) 0.7 Age at onset of rash 3 (3-8) 9 (1-25) <0.001 a 1.11 (1.10-1.13) <0.001 =<4 563 (67.1) 276 (22.5) <0.001 (686.5) 1( Ref. ) 5-9 661 (44.20 235 (19.2) 0.7 (0.5-0.8) 0.002 10-14 206 (13.8) 150 (12.3) 1.4 (1.1-1.9) 0.002 15-29 61 (4.1) 365 (29.8) 12.2 (8.9-16.5) =30 6 (2.9) 198 (97.1) 67.3 (29.5-153.5) <0.001 Address Maekel 784 (74.38) 270 (25.62) < 0.001 (532.2) 1( Ref. ) 1( Ref. ) Anseba 470 (58.6) 332 (41.4) 2 (1.6-2.4) <0.001 2.4 (1.8-3.2) <0.001 Debub 162 (51.43) 153 (48.57) 2.7 (2.1-3.5) <0.001 1.8 (1.2-2.6) <0.001 Gash-Barka 36 (16.0) 189 (84.00) 15.2 (10.4-22.3) <0.001 10.9 (6.1-19.6) <0.001 NRS 44 (15.94) 232 (84.06) 15.3 (10.7-21.7) <0.001 7.6 (4.6-12.7) <0.001 SRS 3 (5.17) 55 (94.83) 53.2 (16.5-171.5) <0.001 23 (4.6-114) <0.001 Health facility Health station 509 (69.1) 228 (30.9) < 0.001 (162.3) 1( Ref. ) 1( Ref. ) Health center 337 (52.6) 304 (47.4) 1.8 (1.4-2.2) <0.001 0.95 (0.72-1.3) 0.7 Hospital 144 (31.37) 315 (68.63) 4.8 (3.7-6.2) <0.001 5.1 (3.6-7.2) <0.001 Year of onset of rash 2015 (2010-2017) 2013 (2010-2016) <0.001 a 0.94 (0.90-0.99) 0.02 =<2014 738 (50.62) 720 (49.38) =2015 761 (59.87) 510 (40.13) 0.6 (0.5-0.8) <0.001 Abbreviations : NRS: Northern Red Sea; SRS: Southern Red Sea; IQR: Interquartile Range. Spatial distribution of measles tests and positive cases from 2002-2020 across Eritrean sub-zones Figure 2 (A-D) presents the distribution of measles by quantiles of the number of serologic tests (T) and positive (P) results in Eritrea from 2002 – 2020. On the main, the figures demonstrate that measles testing is highly heterogeneous and is mostly concentrated in subzones around Maekel (central administrative district) where the testing laboratory is located. Furthermore, between 2017 and 2020, testing in some of the most vulnerable regions was low. Discussion In an era where measles elimination is increasingly becoming a reality even in countries in some of the most disadvantaged parts of the world; sound evidence on incidence, trends, and associated factors at the national and rural level is essential. The current exploratory study aims to investigate these themes in Eritrea. In each and every one of these domains, we discovered multiple standout features. Foremost is the fact that the incidence of measles in Eritrea undulated between moderate to low rate periods over the course of 18 years. Highest CIR > 1 per 100 000 were reported in 2003 (1.79 per 100 000); 2012 (3.6 per 100 000); 2013 (1.38 per 100 000); 2015 (2.52 per 100 000); 2016 (2.14 per 100 000); 2016 (2.13 per 100 000); 2017 (1.58 per 100 000); and 2018 (1.79 per 100 000). These results are in line with data from a recent study on progress towards measles elimination in Eritrea: 2003 – 2018 (8). Importantly, estimates are relatively lower than what has been reported in the African region (567 per 1 million) (15). In a recent work modelling the so-called canonical path to measles elimination, Graham and colleagues argued that in most countries; the path to elimination is tripartite. It begins with regime of uncontrolled endemic transmission regime, characterised by a high incidence of measles and low year-to-year variability. This progresses to a second phase characterised by low incidence but high variability. The final phase is that of the elimination state, i.e. zero incidence and zero variability (16). Based on our data, we can conclude that Eritrea is in the second stage of the canonical path. Indeed, our analysis appears to show that Eritrea has a relatively low incidence of MCV with a high year-to-year variability. In a separate analysis, we demonstrate that Eritrea has lingered in this stage for a relatively long time. Although the present analysis provides a lot of insight on the state of measles elimination efforts in Eritrea, the problem of data reliability should be acknowledged. Indeed, the likelihood that this study has underestimated the incidence of measles in the country is hard to discount. Unlike the Yahdego et al. study which estimated measles incidence based on cases confirmed by laboratory, epidemiological linkage, and clinical criteria (i.e., as if the country is in the pre-elimination phase); our study relied entirely on laboratory confirmed cases. Adoption of this approach was based on the fact that clinical case definition has a limited role in measles case classification in some pre-elimination settings. In other words, the likelihood that measles-like rash symptoms are due to other diseases like Scarlet fever, Rubella, Epstein-Barr virus, Parvovirus B19 Infection (Fifth disease), Chikungunya, and Dengue virus (which are increasingly affecting these populations) is high in some settings. Although outbreaks of Dengue virus, Rubella, and Chikungunya have been reported in Neighboring countries, data from Eritrea is limited. Therefore, the contribution to notified cases is hard to discern. Additionally, we are aware that the exclusive use of laboratory confirmed cases in estimating the incidence of measles incidence in recent years is severely undermined by suboptimal tests of suspected cases. With the exception of 2003, the frequency of serological tests was higher (Minimum 71.23% - Maximum, 100%) prior to 2012; a sharp decline was observed in the subsequent years. In 2017 for instance, the testing frequency of suspected cases reached a nadir of 6.22%. Taking all this into account (even the possibility that a substantial number of suspected cases were due to other causes), the possibility that our study has underestimated the true incidence of measles is substantial. The underreporting of measles can also be attributed to existing surveillance methods. In general, measles surveillance in WHO-AFR is largely based on passive surveillance (based on hospital admissions or contact). In areas where access to hospital or other care facilities is compromised by sub-optimal awareness, poor health seeking behaviour, long distances to facilities, vaccine hesitancy, self-medication, and use of alternative medicine; under-reporting of measles cases is inevitable. As such, reported cases reflect a small proportion of the actual case burden in most countries in WHO-AFR (17). In recent years, potential underreporting of measles cases has been investigated by multiple authors with remarkable results. For example, in the a study conducted in Oromia region in Ethiopia, Poletti et al. reported that the effectiveness of passive surveillance based on hospital admissions or contact decreases dramatically with travel distances from the hospital, becoming negligible beyond 20 - 30 km from the hospital (18). In Kenya, a differently themed study established that admission rates decreased by 11 - 20% per 5-km increase in distance from a care facility (19). In Figure 1, we demonstrated a strong bias in the distribution of health facilities particularly in regions bordering Sudan, Ethiopia, and Djibouti. It should be noted that all these countries have suboptimal MCV coverage – Ethiopia (MCV1 = 59% and MCV2 9% in 2019 (20); Sudan (MCV1 = 90% and MCV2 =72% in 2017) (20), and Djibouti (MCV1=72% and MCV2=82% in 2016) (15). Collectively, the true incidence of measles in hard-to-reach communities that border these countries is hard to gauge. As progress is made toward elimination of measles, knowledge of age distribution patterns in local populations can be crucial for targeted MCV campaigns (16). In this analysis, the age-based analysis of CIR and ASR revealed that measles cases were higher in adolescents and adults. Among the 608 (21.9%) laboratory confirmed cases, 53(9.92%) were <1-year-old. This finding corroborates previous reports that suggested that the median age for measles susceptibility is high and that measles incidence is largely driven by susceptible adolescents and adults (8). According to Prada and colleagues, the achievement of the required MCV thresholds can have a dual impact on the epidemiology of measles – it can lengthen the inter-epidemic period and increase the average / or median age at infection (21).The epidemiological shift to older cohorts is therefore an indicator of progress. From a policy perspective, the data suggests that SIA targeting children from 9 months to 14 years of age (as was the case in 2003-2018) (8) will not reach a significant number of susceptible individuals. The scaling of the measles distribution with age has been linked to multiple factors. First, the distribution of measles can be influenced by birth rates and overall age structure (16). Obviously, high birth rates will skew incidence towards younger cohorts – the converse also applies. Furthermore, we must note the fact that annual vaccine coverage reports in WHO repositories do not involve all age groups. The focus of these reports is mostly restricted to infants. Consequently, WHO country reports often ignore the possible ways in which age-related factors, such as suboptimal vaccination in previous ears (say 20 years ago), vaccine failure (primary or secondary) (22), and temporal variations in vaccine effectiveness or quality, can undermine herd immunity thresholds (23). In Eritrea, for example, MCV1 coverage in 1993 was 34% and sustained MCV1 coverage > 95% was achieved in 2003 (8). Importantly, routine coverage of MCV2 was initiated in 2012 and required thresholds (> 85%) have not been met. Based on these reports, we can conclude that a significant number of young adults and adolescents were either unvaccinated or under vaccinated. Therefore, the increased susceptibility to measles in adolescents and young adults observed in this setting aligns with expectation. This determination is broadly supported by the result showing an 89% decrease in the likelihood of being vaccinated per year of age increase. Furthermore, the possibility that population level of the population may not be as high as the coverage data suggest was recently demonstrated by a study carried out on a small population of Eritreans abroad (average age: 25 years). In this study, the researchers demonstrated that only 76.4% of the study participants had the required concentration of protective antibody titers for measles (24). A different study placed the figure at a marginally higher proportion, 79.9% (25). Together, our data suggest (at least partly) that residual susceptibility inherited from the underperformance of vaccination campaigns (MCV2 in particular (26) in the past decades continues to undermine measles elimination efforts. Therefore, the need for serological surveys (a direct measure of immunity) and more frequent catch-up and follow-up campaigns targeting unvaccinated adolescents and young adults living in rural, hard-to-reach communities is warranted. Further stand-out features of our results include low mortality rates, potential improvements in case notification efficiency, and as previously noted (8); gaps in surveillance performance, particularly, laboratory analysis of suspected cases and epidemiological investigations. In general, much of the discussion on the short-comings of passive surveillance applies to data on measles case fatality rates (CFR). Regarding measles surveillance, we noted a significant under-performance in the laboratory investigation of suspected cases of measles in recent years. The spatial analysis demonstrated a disjunction between regions with higher test rates and regions with measles induced rash. In other words, regions with high prevalence of measles-like symptoms were under-tested. For example, from 2017 to 2020, suspected cases from regions bordering regions (Zone 1 and Zone 2 in the Afar region in Ethiopia) with some of the lowest coverage of MCV1 and MCV2 vaccine coverage (~29.6%) (27, 28) and high incidence of measles in Ethiopia were not tested. Similarly, regions neighbouring Sudan or Djibouti are either under-tested or not tested. Altogether, our results are in line with a previous study in Eritrea which indicated that the country has not attained the 80% target for reporting suspected measles cases with blood specimen since 2011(8). Other investigators in the region have reported similar degeneration in measles surveillance (29). According to the WHO, suspected measles cases should be confirmed in the laboratory using serological tests or Nucleic Acid based tests (RT-PCR). This requirement is based on the assumption that the positive predictive value (PPV) of clinical case definition is low in settings with a low incidence of measles. The problem of low PPV can be compounded by the high prevalence of viruses that can cause morbiliform rashes (30). As noted earlier, the official WHO-UNICEF or WHO Eritrea Biennium Report 2020-2021 (31) suggest that the incidence of measles in Eritrea is low and the prevalence of viruses that can cause measles-like rashes is growing; therefore, comprehensive case investigation, documentation, and reporting is essential. Another allied concern was the observed discrepancy in the number of suspected cases of measles documented in IDSR and the numbers reported in the official WHO-UNICEF Joint Reporting Form (JRF). As noted previously, the discrepancy points to gaps in reporting and the need for data harmonization. In a separate analysis, we investigated the epidemiology of laboratory confirmed measles cases. According to our analysis, the diagnosis of measles was associated with age, address, facility type, vaccination status, and year of the onset of rash. In the logistic regression analysis, we showed that children < 5 – 9 years had a lower likelihood of measles-like rash compared to children < 4 years. This finding is supported by previous research (16) and has been linked to the age of eligibility for MCV. In general, MCV1 is given at 9 months in Eritrea. Therefore, a significant number of children < 1 years are unvaccinated and are thus susceptible to measles. Based on recent trends in MCV coverage, a lower frequency of measles in children aged 5-9 years. As noted previously, the significant age-dependent increase in the likelihood of measles-like rash in individuals > 10 years is probably related to underperformance of vaccination campaigns in the past. Similar to other studies in the region (32), we observed a significant geographical variation in the likelihood of test positivity. Predictably, the likelihood of test positivity was lower in Maekel; the zone where testing is concentrated and vaccine coverage is higher. Regions bordering Sudan (Gash-Barka and NRS) and Ethiopia and Djibouti (SRS) had the highest likelihood of test positivity (and low testing density as noted earlier). Remarkably, SRS which borders regions in Ethiopia with extremely low vaccination coverage (Afar region – Zone 1 and Zone 2 have vaccine coverage <30%) (27, 28); had the highest likelihood of measles test positivity. Furthermore, NRS and Gash-Barka, which border administrative regions in Sudan (Red Sea and Kasala), which have relatively frequent measles outbreaks (33); had a high number of patients with measles-like rash, high test positivity, and low number of tests. Compared to Maekel, the likelihood of being unvaccinated in these regions was relatively high. A similar finding was reported in a previous study (26). Previously, we suggested that parts of NRS, Gash Barka, and SRS have relatively low density of health infrastructure and that this can lead to spatial inequalities in routine vaccine coverage or testing. Another factor that can undermine vaccine coverage in these settings is that fact that some communities living in these regions have nomadic and semi-nomadic lifestyle. Although our analysis has shown a higher measles positivity rate in patients with measles-like rash in NRS, Gash Barka, SRS, and the presence of a host of factors that can undermine measles vaccine coverage, testing or reporting; we are not suggesting that measles may be endemic in these regions. Previous mathematical calculations addressing the epidemiology of measles have shown that a population of 250,000 to 500,000 people is required to establish measles as an endemic disease (16). In contrast, NRS and SRS are sparsely populated and settlements are relatively isolated, suggesting that measles outbreaks are largely due to persistent reintroduction from other areas. Furthermore, social contact clusters in these regions often cut across national borders. This concern was recently reiterated in a WHO report suggesting that despite high measles vaccines in Eritrea, the country is at risk of measles importation due to cross-border population movement and potential population mix dynamics (31). Additional support for this conclusion is related to the fact that the impact of low vaccination coverage and the endemicity of measles in surrounding countries is known to be more pronounced in smaller countries like Eritrea (16). However, in the absence of realistic data on social mixing patterns in cross-border communities and genotypic data; tracking of the sources of outbreaks or transmission chains in the country is difficult. In summary, we conclude that even if the conditions for the elimination of measles elimination (MCV1 >95% and MCV2 > 85% in all regions) are met in Eritrea; sustained elimination will be difficult due to the high odds of transmission across the border from highly impacted, under-vaccinated sub-regions in Sudan and Ethiopia. Therefore, the importance of regional coordination of elimination efforts and robust surveillance in NRS, SRS, and Gash-Barka cannot be overemphasised. Last but not least, we showed that patients in hospitals had a higher probability of test positivity compared to patients from health centres / stations. A plausible explanation for this finding relates to the possibility that patients with measles-related complications are usually referred by primary health clinics (PHC) to hospitals where trained physicians are stationed. Unlike caregivers in PHCs; physicians in hospitals may be better at diagnosis and profiling. Separately, we found a connection between measles test positivity and vaccination. This outcome is supported by previous studies done in Ethiopia (18, 34), South Sudan (35), and Gambia (32). Interestingly, individuals who were vaccinated before 2010 had a higher likelihood of measles test positivity. At present, we have no obvious explanation for this outcome. However, we believe that the proximity between this timeline and the initiation of MCV2 coverage in 2012 is not coincidental. Strength and Limitation Unlike previous work which utilized data from WHO/UNICEF Joint Reporting Form (JRF) and administrative data, we sourced our data from the national and sub-national representative DHS database. This notwithstanding, our study suffers from a number of limitations including inconsistencies in measles testing between subregions and over time. Additionally, information on vaccination status was based, to a large extent, on self-reported responses. Therefore, social desirability bias cannot be discounted. Last but not least, retrospective studies typically suffer from missing data problems, and we believe that this study was not an exception. Conclusion Our report suggests that Eritrea has a relatively low incidence of measles but a high variability year-to-year. However, the potential for under-estimation of cases exists due to under-reporting of suspected cases and incomplete testing, particularly in recent years. Furthermore, age-based analysis of CIR and ASR revealed that the median age for measles cases was 7 years (IQR: 4-14 years). This means that SIV campaigns targeting individuals < 14 years will miss a large proportion of individuals with residual susceptibility. Laboratory positivity for measles was associated with increasing age, residence in border regions (Gash-Barka, SRS, and NRS), level of care facility, vaccination status, and year of onset of measles-like rash. Interestingly, uptake of MCV was associated with a similar complement of factors. In a separate analysis, we demonstrated that despite the high coverage of MCV in Eritrea, spatial inequalities in vaccine coverage or surveillance and extremely low vaccination rates in specific subregions in neighboring countries continue to undermine elimination efforts. To address these issues, there should be more focus on regional microplanning to create efficient systems for monitoring, reporting, and management of outbreaks. Additional strategies can include decentralisation of testing; targeted serological surveys; ring vaccination in border areas; more frequent catch-up SIAs targeting unvaccinated adults and adolescents; building capacity for genetic testing of isolates, and enhancing regional coordination of elimination efforts. Declarations Funding: This research received no external funding. Institutional Review Board Statement : The study was carried out according to the Declaration of Helsinki and was approved by Ethical Committee of the Eritrean Ministry of Health. Written consent was not obtained from the patients. Instead, the data was de-identified and all ethical and professional considerations undergirding confidentiality/or others protections of patient information were rigorously implemented. Data Availability Statement : Data are not publicly available due to privacy and confidentiality. Restrictions apply to the availability of data, but are available for the authors with the permission of the organisation. Acknowledgements: Conflicts of Interest : The authors declare no conflict of interest. Authors’ contribution: S.T.M. conceived and designed the study. S.T.M., A.T.T., F.T., I.M., M.S., D.F., H.A., R.M., T.T., and L.G.W. participated in the performed data collection. S.T.M., and O.O.A. did the statistical analysis and spatial mapping. STM, O.O.A., M.E.H., and W.Y.W. did the data presentation, and reviewed/edited the manuscript. All authors read and approved the final manuscript. References Laksono BM, de Vries RD, McQuaid S, Duprex WP, de Swart RL. Measles Virus Host Invasion and Pathogenesis. Viruses. 2016 Jul 28;8(8). eng. Epub 2016/08/03. doi:10.3390/v8080210. Cited in: Pubmed; PMID 27483301. de Vries RD, Duprex WP, de Swart RL. Morbillivirus infections: an introduction. Viruses. 2015 Feb 12;7(2):699-706. eng. Epub 2015/02/17. doi:10.3390/v7020699. Cited in: Pubmed; PMID 25685949. Factsheet W. Measles. 2023 3 May. Available from: https://www.who.int/news-room/fact-sheets/detail/measles. Wang R, Jing W, Liu M, Liu J. Trends of the global, regional, and national incidence of measles, vaccine coverage, and risk factors in 204 countries from 1990 to 2019. Frontiers in Medicine. 2022;8:2885. Thompson KM. What will it take to end human suffering from measles? The Lancet Infectious Diseases. 2017;17(10):1013-1014. Moss WJ, Shendale S, Lindstrand A, O'Brien KL, Turner N, Goodman T, Kretsinger K. Feasibility assessment of measles and rubella eradication. Vaccine. 2021;39(27):3544-3559. Organisation WH. Regional Committee for Africa. Measles elimination by 2020: a strategy for the African Region. 2020 4 May. Available from: https://www.afro.who.int/sites/default/files/sessions/working_documents/AFR-RC61-8-Measles-elimination-by-2020---strategy-forthe-African-Region---with-Resolution.pdf. Yehdego T, Yhdego TK, Masresha B, Gebreslassie A, Katsande R, Fussum D, Lebo E, Namboze J. Progress towards measles elimination in Eritrea: 2003 - 2018. Pan Afr Med J. 2020;35(Suppl 1):7. eng. Epub 2020/05/07. doi:10.11604/pamj.supp.2020.35.1.19126. Cited in: Pubmed; PMID 32373258. Masresha BG, Kaiser R, Eshetu M, Katsande R, Luce R, Fall A, Dosseh AR, Naouri B, Byabamazima CR, Perry R, Dabbagh AJ, Strebel P, Kretsinger K, Goodson JL, Nshimirimana D. Progress toward measles preelimination--African Region, 2011-2012. MMWR Morb Mortal Wkly Rep. 2014 Apr 4;63(13):285-91. eng. Epub 2014/04/05. Cited in: Pubmed; PMID 24699765. Organization WH. World health statistics 2018: monitoring health for the SDGs, sustainable development goals. World Health Organization; 2018. ISBN: 9241565586. Organization WH. African regional guidelines for measles and rubella surveillance. African Regional guidelines for measles and rubella surveillance-Draft version April. 2015. Getahun M, Beyene B, Ademe A, Teshome B, Tefera M, Asha A, Afework A, HaileMariyam Y, Assefa E, Gallagher K. Epidemiology of laboratory confirmed measles virus cases in Amhara Regional State of Ethiopia, 2004–2014. BMC infectious diseases. 2016;16(1):1-7. Mitiku K, Bedada T, Masresha BG, Kegne W, Nafo-Traoré F, Tesfaye N, Yigzaw A. Progress in measles mortality reduction in Ethiopia, 2002-2009. J Infect Dis. 2011 Jul;204 Suppl 1:S232-8. eng. Epub 2011/06/17. doi:10.1093/infdis/jir109. Cited in: Pubmed; PMID 21666166. Office NS. Eritrea Demographic and Health Survey 1995 1997 4 May. Available from: https://dhsprogram.com/pubs/pdf/FR80/FR80.pdf. Patel MK, Goodson JL, Alexander JP, Jr., Kretsinger K, Sodha SV, Steulet C, Gacic-Dobo M, Rota PA, McFarland J, Menning L, Mulders MN, Crowcroft NS. Progress Toward Regional Measles Elimination - Worldwide, 2000-2019. MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1700-1705. eng. Epub 2020/11/13. doi:10.15585/mmwr.mm6945a6. Cited in: Pubmed; PMID 33180759. Graham M, Winter AK, Ferrari M, Grenfell B, Moss WJ, Azman AS, Metcalf CJE, Lessler J. Measles and the canonical path to elimination. Science. 2019;364(6440):584-587. Jani JV, Jani IV, Araújo C, Sahay S, Barreto J, Bjune G. Assessment of routine surveillance data as a tool to investigate measles outbreaks in Mozambique. BMC infectious diseases. 2006;6:1-9. Poletti P, Parlamento S, Fayyisaa T, Feyyiss R, Lusiani M, Tsegaye A, Segafredo G, Putoto G, Manenti F, Merler S. The hidden burden of measles in Ethiopia: how distance to hospital shapes the disease mortality rate. BMC Med. 2018 Oct 18;16(1):177. eng. Epub 2018/10/20. doi:10.1186/s12916-018-1171-y. Cited in: Pubmed; PMID 30333039. Manakongtreecheep K, Davis R. A review of measles control in Kenya, with focus on recent innovations. Pan Afr Med J. 2017;27(Suppl 3):15. eng. Epub 2018/01/04. doi:10.11604/pamj.supp.2017.27.3.12118. Cited in: Pubmed; PMID 29296150. Yehualashet DE, Seboka BT, Tesfa GA, Mamo TT, Seid E. Determinants of optimal antenatal care visit among pregnant women in Ethiopia: a multilevel analysis of Ethiopian mini demographic health survey 2019 data. Reproductive Health. 2022;19(1):1-8. Ferrari MJ, Grenfell BT, Strebel PM. Think globally, act locally: the role of local demographics and vaccination coverage in the dynamic response of measles infection to control. Philos Trans R Soc Lond B Biol Sci. 2013 Aug 5;368(1623):20120141. eng. Epub 2013/06/27. doi:10.1098/rstb.2012.0141. Cited in: Pubmed; PMID 23798689. Moss W. Measles in vaccinated individuals and the future of measles elimination. Oxford University Press US; 2018. p. 1320-1321. Preeta Kutty JR, William Bellini, Susan B. Redd, Albert Barskey, Wallace G. Vaccine-Preventable Diseases Surveillance Manual: Measles: CDC; 2013. . 2013 5 May. Available from: http://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.pdf. Staehelin C, Chernet A, Sydow V, Piso RJ, Suter-Riniker F, Funez S, Nickel B, Paris DH, Labhardt ND. Seroprotection rates of vaccine-preventable diseases among newly arrived Eritrean asylum seekers in Switzerland: a cross-sectional study. Journal of travel medicine. 2019;26(6):taz035. Ceccarelli G, Vita S, Riva E, Cella E, Lopalco M, Antonelli F, De Cesaris M, Fogolari M, Dicuonzo G, Ciccozzi M. Susceptibility to measles in migrant population: implication for policy makers. Journal of travel medicine. 2018;25(1):tax080. Kibreab F, Lewycka S, Tewelde A. Impact of mother’s education on full immunization of children aged 12–23 months in Eritrea: population and health survey 2010 data analysis. BMC Public Health. 2020;20:1-10. Geremew TT, Gezie LD, Abejie AN. Geographical variation and associated factors of childhood measles vaccination in Ethiopia: a spatial and multilevel analysis. BMC public health. 2019;19:1-15. Tesfa GA, Demeke AD, Hailegebreal S, Amede ES, Ngusie HS, Kasie MN, Seboka BT. Spatial distribution and associated factors of measles vaccination among children aged 12–23 months in Ethiopia. A spatial and multilevel analysis. Human Vaccines & Immunotherapeutics. 2022;18(1):2035558. Altez MR. Appropriate/Measles Vaccination Is Key for Prevention of Subacute Sclerosing Panencephalitis. The Journal of Pediatrics. 2022;246:1-3. Hutchins SS, Papania MJ, Amler R, Maes EF, Grabowsky M, Bromberg K, Glasglow V, Speed T, Bellini WJ, Orenstein WA. Evaluation of the measles clinical case definition. J Infect Dis. 2004 May 1;189 Suppl 1:S153-9. eng. Epub 2004/04/24. doi:10.1086/379652. Cited in: Pubmed; PMID 15106104. 2021 WEBR. Consolidating Achievement of UHC in Eritrea. WHO. . 2021 4 May Available from: https://www.afro.who.int/sites/default/files/2022-07/Who%20Eritrea%20Bienniun%20Report%20WHO%202020%20-%202021_0.pdf. Sowe A, Njie M, Sowe D, Fofana S, Ceesay L, Camara Y, Tesfaye B, Bah S, Bah AK, Baldeh AK, Dampha BD, Baldeh SN, Touray A. Epidemiology of measles cases, vaccine effectiveness, and performance towards measles elimination in The Gambia. PLoS One. 2021;16(10):e0258961. eng. Epub 2021/10/22. doi:10.1371/journal.pone.0258961. Cited in: Pubmed; PMID 34673828. Sabahelzain MM, Moukhyer M, Bosma H, van den Borne B. Determinants of measles vaccine hesitancy among Sudanese parents in Khartoum State, Sudan: a cross-sectional study. Vaccines. 2022;10(1):6. Girmay A, Dadi AF. Being unvaccinated and having a contact history increased the risk of measles infection during an outbreak: a finding from measles outbreak investigation in rural district of Ethiopia. BMC Infect Dis. 2019 Apr 25;19(1):345. eng. Epub 2019/04/27. doi:10.1186/s12879-019-3973-8. Cited in: Pubmed; PMID 31023269. Mokaya EN, Isaac Z, Anyuon NA. Measles outbreak investigation in Aweil East county, South Sudan. Pan Afr Med J. 2021;40:87. eng. Epub 2021/12/16. doi:10.11604/pamj.2021.40.87.28370. Cited in: Pubmed; PMID 34909076. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-2905015","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":198295390,"identity":"3f6f3a8e-09c4-4557-9ba2-5415eeb7c7df","order_by":0,"name":"Samuel Tekle Mengistu","email":"","orcid":"https://orcid.org/0000-0002-2817-1421","institution":"Nakfa Hospital, Ministry of health Northern Red Sea branch, Nakfa, Eritrea.","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Samuel","middleName":"Tekle","lastName":"Mengistu","suffix":""},{"id":198295391,"identity":"f4068c25-9d97-4fac-bd47-82adb47ebfaf","order_by":1,"name":"Oliver Okocht Achila","email":"","orcid":"https://orcid.org/0000-0001-8013-0785","institution":"Orotta college of medicine and health sciences, unit of clinical laboratory sciences, Asmara, Eritrea.","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Oliver","middleName":"Okocht","lastName":"Achila","suffix":""},{"id":198295392,"identity":"12d8bdca-7ce8-42e1-ab9b-d254faed3a6b","order_by":2,"name":"Asmerom Tesfagiorgis Tewelde","email":"","orcid":"","institution":"IDSR, CDC, Ministry of Health, Asmara, Eritrea","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Asmerom","middleName":"Tesfagiorgis","lastName":"Tewelde","suffix":""},{"id":198295393,"identity":"c1150fc1-79e8-4828-91ff-d945ba42efd4","order_by":3,"name":"Mohammed Elfatih Hamida","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA9UlEQVRIiWNgGAWjYFACHgaGBzYMDGwS/N9/fADy2diJ0ZKQxiDBJsFgIDkDpIWZWC1AaCDNAxIgpEW3vffgg4QEuzo+6YYEY5tf2+T5mBkYP3zMwa3F7My5ZIOEhGQJNpkDB5Jz+24btjEzMEvO3IZHy40cM4nEH8xAvyQ2HM7tuc0I1MLGzItfi/mPhIR6oJZkxmbLntv2xGgxY0hIOAzUksbMzPDjdiJhLWfOGEskJByXbJPIYWPsbbid3MbM2IzfL8d7DD98SKjml5+Rw8bw489t2/ntzQc/fMSjBRUwtoHJBmLVg8AfUhSPglEwCkbBSAEAFNNMOSMbb2AAAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0002-5337-399X","institution":"Orotta college of medicine and health sciences, unit of microbiology, Asmara, Eritrea.","correspondingAuthor":true,"submittingAuthor":false,"prefix":"","firstName":"Mohammed","middleName":"Elfatih","lastName":"Hamida","suffix":""},{"id":198295394,"identity":"33dec14f-9e64-4827-806d-841795d14019","order_by":4,"name":"Freweini Tekle","email":"","orcid":"","institution":"Serology department, National Health laboratory, Asmara, Eritrea","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Freweini","middleName":"","lastName":"Tekle","suffix":""},{"id":198295395,"identity":"2bf51ed4-3c39-44e4-a450-bfd9be8aff3a","order_by":5,"name":"Issaias Michae","email":"","orcid":"","institution":"Serology department, National Health laboratory, Asmara, Eritrea","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Issaias","middleName":"","lastName":"Michae","suffix":""},{"id":198295396,"identity":"6ff1e65f-c584-4903-be4a-d35d1495b199","order_by":6,"name":"Mensura Said","email":"","orcid":"","institution":"Serology department, National Health laboratory, Asmara, Eritrea","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Mensura","middleName":"","lastName":"Said","suffix":""},{"id":198295397,"identity":"d099301f-38a1-47c1-8318-c9b3449c6b0e","order_by":7,"name":"Dawit Fsahatsion","email":"","orcid":"","institution":"Serology department, National Health laboratory, Asmara, Eritrea","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Dawit","middleName":"","lastName":"Fsahatsion","suffix":""},{"id":198295398,"identity":"74a54195-4ce3-484b-89af-56c073ff8e1a","order_by":8,"name":"Haimanot Abai","email":"","orcid":"","institution":"Serology department, National Health laboratory, Asmara, Eritrea","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Haimanot","middleName":"","lastName":"Abai","suffix":""},{"id":198295399,"identity":"9d37082c-9e37-4570-a2b2-3a0ccd0913a1","order_by":9,"name":"Rahel Mulugeta","email":"","orcid":"","institution":"Serology department, National Health laboratory, Asmara, Eritrea","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Rahel","middleName":"","lastName":"Mulugeta","suffix":""},{"id":198295400,"identity":"4eb24d09-0014-44c9-a18d-bff37d22a879","order_by":10,"name":"TsigehanaTsegai","email":"","orcid":"","institution":"Serology department, National Health laboratory, Asmara, Eritrea Email:","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"","middleName":"","lastName":"TsigehanaTsegai","suffix":""},{"id":198295401,"identity":"82b114b5-d385-4b91-90f6-a4747bc7f598","order_by":11,"name":"Luwam Gilazghi Woldu","email":"","orcid":"","institution":"Serology department, National Health laboratory, Asmara, Eritrea","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Luwam","middleName":"Gilazghi","lastName":"Woldu","suffix":""},{"id":198295402,"identity":"6f12b758-2d45-44e0-8931-d6363f3fd3fc","order_by":12,"name":"Wintana Yebio Werke","email":"","orcid":"","institution":"Keren Hospital, Ministry of Health, Anseba branch, Keren, Eritrea","correspondingAuthor":false,"submittingAuthor":false,"prefix":"","firstName":"Wintana","middleName":"Yebio","lastName":"Werke","suffix":""}],"badges":[],"createdAt":"2023-05-07 17:36:40","currentVersionCode":1,"declarations":{"humanSubjects":false,"vertebrateSubjects":true,"conflictsOfInterestStatement":true,"humanSubjectEthicalGuidelines":false,"humanSubjectConsent":false,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":true,"coiExplicitlySet":false},"doi":"10.21203/rs.3.rs-2905015/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-2905015/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":36758784,"identity":"54683cad-2276-47ca-a854-17217bb9e6c8","added_by":"auto","created_at":"2023-05-09 20:19:16","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":360703,"visible":true,"origin":"","legend":"\u003cp\u003eDistribution of health facilities across Eritrea presented by Kernel density. The red lines represent the main road connecting the different parts of the country\u003c/p\u003e","description":"","filename":"1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-2905015/v1/881af944d7849751d389296e.jpg"},{"id":36758785,"identity":"5593de16-96a2-4e7c-bb92-73ccbf1fe177","added_by":"auto","created_at":"2023-05-09 20:19:16","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":513086,"visible":true,"origin":"","legend":"\u003cp\u003eGeospatial symbology for the distribution of measles by quantiles of numbers of serologic tests (T), and positive (P) results across the country. Figure A represents for the year band of 2002-2009. Figure B represent 2010-2012. Figure C represent 2013-2016 and Figure D is for 2017-2020.\u003c/p\u003e","description":"","filename":"2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-2905015/v1/bbc20897f2daca71485be5d9.jpg"},{"id":36758786,"identity":"0acf767c-4a42-442d-8859-a7b13f258486","added_by":"auto","created_at":"2023-05-09 20:19:22","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":895305,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-2905015/v1/789588a4-2089-4916-858f-28dfa0be43af.pdf"}],"financialInterests":"","formattedTitle":"\u003cp\u003e\u003cstrong\u003eEpidemiology of confirmed measles virus cases, surveillance, incidence, and associated factors in Eritrea: 18-year retrospective analysis\u003c/strong\u003e\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003eMeasles virus (MV), a member of the genus \u003cem\u003eMorbilivirus\u003c/em\u003e, family \u003cem\u003eParamyxoviridae\u003c/em\u003e, is an antigenically monotypic, enveloped, single-stranded (SS) virus with a non-segmented negative (-) sense RNA genome (1). Like other \u003cem\u003eMorbiliviruses\u003c/em\u003e, MV is highly contagious (basic reproductive number (R\u003csub\u003e0\u003c/sub\u003e\u0026thinsp;=\u0026thinsp;10\u0026ndash;18) and can cause multiple complications (1). Following exposure \u003cem\u003eby\u003c/em\u003e respiratory route or contact with respiratory droplets, up to 90% of susceptible people can develop systemic infection within 10\u0026ndash;14 days (up to 3 weeks in adults) (2). The 1 to 3 day prodromal phase is hallmarked by fever, malaise, and the three C (cough, coryza, and conjunctivitis) (3). A common finding at this stage is Koplik\u0026rsquo;s spot and an erythematous maculopapular rash. Although MV infection is self-limiting, common sequelae include transient immunosuppression, diarrhea, otitis media, laryngotracheobrochitis, pneumonia (accounts for 90% of measles mortality), and post-viral encephalitis. On rare occasions, it can lead to subacute sclerosing panencephalitis, a potentially fatal central nervous system (CNS) complications (1).\u003c/p\u003e \u003cp\u003eBefore the introduction of the measles vaccine in the 1960s, MV epidemics occurred periodically (every 2 to 3 years), with approximately 2.6\u0026nbsp;million mortalities annually (3). However, the scale-up of vaccine coverage, particularly in low- and middle-income countries (LMICs) in the 1990s triggered a significant decline in incidence, morbidity, and mortalities (4). Based on measles case-based surveillance data in Africa, the number of cases decreased from 520,102 cases in 2000 to 98,621 cases in 2015 translating into a corresponding incidence decline of 841 per 1000,000 to 100 per 1000,000 in the same period (3). The report also concluded that measles vaccination [measles-containing vaccine 1 (MCV1), measles-containing vaccine 2 (MCV 2) and supplemental immunization activities (SIAs)] prevented 23.2\u0026nbsp;million deaths from 2000\u0026ndash;2018 (3). Importantly, declines in mortality have paralleled steep declines in MV-associated disability-adjusted life-years (DALYs). From 1990 to 2019, the DALY rates decreased from 2.7 (Uncertainty interval (UI):0.9\u0026ndash;5.6) to 0.3 (UI: 0.1\u0026ndash;0.6), translating into a percentage change of -89.8%(-92.3%-86.8%) (5). However, measles still account for a significant number of deaths globally (\u0026gt;\u0026thinsp;140,000 persons in 2018, mostly children\u0026thinsp;\u0026lt;\u0026thinsp;5 years) (6).\u003c/p\u003e \u003cp\u003eBy most accounts, the remarkable decline in the burden of measles in Sub-Saharan Africa (SSA) is closely intertwined with multiple policy prescriptions of the World Health Organisation (WHO) policy prescription. In 2008, following the earlier standards set by the 2006\u0026ndash;2015 Global Immunisation Vision and Strategy; the WHO adopted its four-point pre-elimination plan for the African Region (AFR) (7). These included: 1)\u0026thinsp;\u0026gt;\u0026thinsp;98% reduction in measles mortality with the year 2000 as the baseline, 2) annual incidence of measles incidence\u0026thinsp;\u0026lt;\u0026thinsp;5 per 1,000,000 cases nationally, 3)\u0026thinsp;\u0026gt;\u0026thinsp;90% MCV1 coverage nationally\u0026thinsp;\u0026gt;\u0026thinsp;80% coverage in districts, and 4)\u0026thinsp;\u0026gt;\u0026thinsp;95% SIA in all districts. Specific surveillance performance objectives were also embedded in the document. In 2011, these goals were adopted by the WHO AFR 2020 measles elimination plan, and subsequently incorporated into its regional immunization strategic plan (7).\u003c/p\u003e \u003cp\u003eIn Eritrea, the Expanded Programme on Immunisation (EPI) began in 1980 (pre-independence era). The original EPI included the provision of the first dose of measles-containing vaccine (MCV1) at 9 months of age. However, the coverage of MCV1 in this period was very low, 34% (8). In 2003, the country implemented SIAs. This was followed by the implementation of case-based surveillance in 2005, and MCV2 in 2012. According to the WHO-AFR goals, and its second national Strategic Development Plan (HSSDP-II) (2017\u0026ndash;2021); Eritrea adopted the \u0026gt;\u0026thinsp;95% (MCV1)-90% (MVC2) as a primary part of its national multiyear plan for immunization. Currently, the WHO and United Nations Children\u0026rsquo;s Fund (WHO/UNICEF) score card on vaccination estimates suggest that Eritrea has consistently reported\u0026thinsp;\u0026gt;\u0026thinsp;95% MCV1 since 2003 and \u0026gt;\u0026thinsp;88% MCV2 coverage since 2015 (8).\u003c/p\u003e \u003cp\u003eAlthough the adoption of these policies was broadly successful; The MCV2 and SIAs targets, surveillance performance targets, and incidence rates\u0026thinsp;\u0026lt;\u0026thinsp;5 per 1,000,000 cases nationwide were not met (9). In other settings across WHO-AFR regions, underperformance in these indicators has been associated with poor access to community-linked immunization services; inadequate infrastructure for laboratory-supported case-based surveillance, poor quality of data, and reduction in vaccine effectiveness, among others (9). Importantly, others have opined that national WHO-UNICEF estimates (vaccination or measles burden) can mask within-country disparities, and context-specific social and economic drivers of measles infections. For this reason, clusters of unvaccinated or under-vaccinated individuals are known to exist even in countries with relatively high MCV coverage. To remedy this situation, renewed research effort is required, particularly in hard-to-reach communities, is required. Such investigations should also focus on spatiotemporal heterogeneity in measles incidence, testing and MCV coverage. Equally vital is the need to understand demographic correlates of measles infection at the local level. In this analysis, our objective was to evaluate the incidence and spatiotemporal distribution of measles in Eritrea. Furthermore, an evaluation of the factors associated with measles vaccination and IgM positive (+) febrile rash was attempted.\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eStudy design, population, and settings\u003c/h2\u003e \u003cp\u003eWe conducted a retrospective analysis of data collected in Eritrea from 2002\u0026ndash;2020. Eritrea is a country located in the upper part of the Horn of Africa. The country is bounded to the east by the Red Sea; to the North and west by Sudan; to the South by Ethiopia and to the South East by Djibouti. It has a surface area of ~\u0026thinsp;124,000 Km\u003csup\u003e2\u003c/sup\u003e and a total population of 3,905,066, including\u0026thinsp;~\u0026thinsp;117 152 surviving infants as of 2022. According to the Inter-Agency Group of the United Nations for Child Mortality Estimation, the mortality rate, and infant mortality rate in 2020 were 38 per 1,000 live births and 18 per 1,000 live births, respectively(10). Administratively, the country is divided into six \u003cem\u003eZobas\u003c/em\u003e (regions): Maekel (central region), Gash Barka, Anseba, Debub, Debubawi Keih Bahri (DKB) (Southern Red Sea) and Semienawi Keih Bahri (SKB) (Northern Red Sea). The regions are further subdivided into 58 sub-zones, 699 administrative areas, and 2564 villages. Healthcare is provided, almost exclusively, by the Eritrea Ministry of Health through a three-tier system, namely primary care level (serves\u0026thinsp;~\u0026thinsp;500\u0026ndash;2000 people), secondary care level (serves\u0026thinsp;~\u0026thinsp;5,000\u0026ndash;10 000) and tertiary care level (serves\u0026thinsp;~\u0026thinsp;50,000\u0026ndash;100 000). Using the reaching every district approach, the country\u0026rsquo;s EPI program, which is housed as a unit within the Department of Public Health; delivers immunization services, 6 days per week, through 302 (85%) health facilities and 450 outreach sites (8). In addition, country implements Periodic Intensified Routine Immunization (PIRI) services, every quarter for nomadic and semi-nomadic population groups and people living in 16 hard-to-reach districts. As of December 2021, the national immunization target includes antigens against 12 vaccine preventable diseases. Overall, data from vaccination cards and mother\u0026rsquo;s reports suggest that in 2020, 99.4%, 98.9%, 98.8% and 96.9% received required doses of Bacillus Calmette Gu\u0026eacute;rin (BCG) vaccine, oral polio vaccine (OPV), PENTA-3 (vaccine for Hepatitis B virus (HBV), Diptheria-Pertussis-Tetanus (DPT), Haemophilus influenza type b) and measles-mumps-rubella (MMR) - MCV (MCV1 at 9 months and MCV2 at 15 months), respectively.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eData Source and Study Variables\u003c/h3\u003e\n\u003cp\u003eIn Eritrea, the national serological laboratory conducts measles case-based surveillance to confirm measles cases is undertaken by the national serological laboratory. The surveillance protocols used by the measles serological laboratory are based on WHO-AFR standards (11). It includes individual case investigation and blood specimen collection for laboratory testing (9) in national or regional reference laboratories. At present, molecular techniques (real-time polymerase chain reaction (RT-PCR) and sequence analysis) or cell culture are not available in the national laboratory. In general, the data used in this analysis were from the primarily obtained integrated disease surveillance and response database (IDSR). The database contains information on the number of measles tests conducted per year at the National Hospital Laboratory (the only testing center in Eritrea). The data used for age standardization were obtained from the Eritrea Statistics Office. The variables considered in this analysis included total notified cases, number of notified cases which were tested, positive immunoglobulin M (IgM) (+), Ig M-/ Intermediate, and epidemiological linked cases (EPI-linked), and final outcome of MCV infection. Additional information included patient sex, age at onset of rash, address, health facility, vaccination status, last vaccination, and date of the onset of rash.\u003c/p\u003e\n\u003ch3\u003eData Collection Procedures and data quality\u003c/h3\u003e\n\u003cp\u003eIn this study, data (spanning the period from 2002 to 2020) was abstracted IDSR using a form designed for this purpose. The variables captured included age at the beginning of the rash, years, address (region / zone), facility level, vaccination status, and last vaccination. To ensure compliance with specific ethical requirements, all participant data were de-identified. At this stage, the data were managed using CSPro software (version 7.0).\u003c/p\u003e\n\u003ch3\u003eOperational Definitions\u003c/h3\u003e\n\u003cp\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eA suspected measles case was defined according to the WHO-AFR Measles and Rubella Surveillance Guideline [WHO-AFR] \u0026ndash; persons with a generalized maculopapular rash, fever, plus one or more of the following: coryza, cough, conjunctivitis, OR any person in whom a clinician suspects measles (12).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eA confirmed measles case was defined as the presence of measles-specific IgM antibodies (IgM\u003csup\u003e+\u003c/sup\u003e) of a titer that exceeded the thresholds indicative of infection in people without evidence of vaccination in the last 30 days (13).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eEpidemiologically linked case refers to a suspected case that has been linked (in person, place, and time) to a laboratory confirmed case (13).\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eA non-measles case was defined as any notified case/suspected case that was measles-specific IgM (-) after testing as per established protocols.\u003c/p\u003e \u003c/li\u003e \u003cli\u003e \u003cp\u003eThe status of measles vaccination was categorized into vaccination (at least MCV1), non-vaccination, and unknown status.\u003c/p\u003e \u003c/li\u003e \u003c/ul\u003e \u003c/p\u003e\n\u003ch3\u003eMain results of the study\u003c/h3\u003e\n\u003cp\u003eThe outcome variables included the crude incidence rate (CIR), age adjusted incidence rates, and age-specific measles IgM positivity. Additional outcomes included factors associated with measles-specific IgM positive febrile rash and vaccination. The spatial distribution of measles tests and positive cases from 2002\u0026ndash;2020 across Eritrean sub-zones was also evaluated.\u003c/p\u003e\n\u003ch3\u003eStatistical Analyses\u003c/h3\u003e\n\u003cp\u003eData was analysed using IBM\u0026reg; SPSS\u0026reg; Statistics for Windows, version 26 (IBM Corp., Armonk, N.Y., USA). Crude incidence rates (CIR), age standardised rates (ASR), and specific measures of central tendency, medians (\u0026plusmn;\u0026thinsp;Interquartile ranges (IQR)) and means (\u0026plusmn;\u0026thinsp;standard deviations (SD) were computed where applicable. The CIR was calculated by diving the total number of confirmed cases (by laboratory serology) per year or age category as the number of the total population. The numbers used in these denominators were obtained from the Eritrea National Statistics Office (14). To test for differences in medians or frequencies between groups, Kruskal-Wallis, Mann-whitney U, or Chi-squire statistics ( 2) were used. Subsequently, binary logistic regression models were fitted to identify the predictors of measles test positivity or vaccine uptake of vaccine in the population. The results were finally presented in tables, graphs, and figures. Furthermore, the spatial variability in the tests and the distribution of confirmed cases during the study period was calculated using ArcGIS version 10.1.\u003c/p\u003e\n\u003ch3\u003eEthical Considerations\u003c/h3\u003e\n\u003cp\u003eThe study was carried out according to the Declaration of Helsinki and was approved by Ethical Committee of the Eritrean Ministry of Health (EMH). Written consent was not obtained from the patients. Instead, the data were identified and all ethical and professional considerations undergirding confidentiality/or others protections of patient information were rigorously implemented.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eFrom 2002 to 2020, ~ 9,111 cases of febrile rash notifications were reported in Eritrea. However, of 2,767 (30.4%) cases were tested; MV IgM was 607 (21.9%) and 82 (3% of the tested) were epidemiologically linked. Mean (\u0026plusmn;\u0026thinsp;SD), 10.5 months (\u0026plusmn;\u0026thinsp;10.4 months) with a minimum age \u0026ndash; maximum age of the cases was 1 month and 97 months, respectively. The overall CIR of MV was 14 per 100,000. Overall, 17 (3% of the total measles) cases died due to measles and/or its complications. This translates into a reported MV-related death rate of 24.6 per 1,000. See Table \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003e.\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003ctable id=\"Tab1\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003eDistribution of measles serologic test results across years from 2002\u0026ndash;2020 in Eritrea\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eYear\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eTotal cases notified\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eTested n(%)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eIgM+\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eIg M-/ Intermediate\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eEpi link\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eCrude rate per 100,000\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eMeasles death\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003eMDR/1000\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2002\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e85\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e79 (93)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e23\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e56\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.8841\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2003\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e363\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e99 (27)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e48\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e51\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e21\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.7969\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e14.5\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2004\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e48\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e40 (83)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e31\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.3417\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2005\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e95\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e89 (94)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e14\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e75\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.5166\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2006\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e134\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e128(96)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e125\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.1076\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1000\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2007\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e58\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e58(100)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e58\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.03486\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2008\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e65\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e64(98)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e64\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.03389\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2009\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e73\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e52(71)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e49\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.0988\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2010\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e171\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e171(100)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e166\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.1601\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2011\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e147\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e147(100)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e14\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e133\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.4357\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2012\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e682\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e305(45)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e119\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e186\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e40\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6.2\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2013\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e621\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e150(24)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e47\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e103\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.382\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e85\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2014\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e127\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e114(90)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e113\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.0285\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2015\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e468\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e202(43)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e91\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e111\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2.528\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e65.9\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2016\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e726\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e364(50)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e79\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e285\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2.1378\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2017\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e3,150\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e196(6.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e60\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e136\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.5794\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e16.6\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2018\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e1,023\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e176(17)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e70\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e106\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.7925\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2019\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e545\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e191(35)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e183\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.1993\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2020\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e620\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e142(23)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e13\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e129\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.3151\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eTotal\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e9,111\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2,767(30.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e607\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e2,160\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e82\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e14\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"char\"\u003e\n\u003cp\u003e17\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e24.6\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eDefinition:\u003c/strong\u003e Attack rates; Number of measles/ total number of patients tested.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAbbreviations:\u0026nbsp;\u003c/strong\u003eMDR; measles death rate\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCrude incidence rate, age adjusted incidence rates, and age-specific measles IgM positivity\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn this analysis, a higher CIR and age-specific incidence of measles was observed in adults: =\u0026lt; 4 years, 11.7 per 100 samples tested; 5-9 years, 8.6 per 100 samples tested; 9-14 years, 17.4 per 100 samples tested; 15-29 years, 49.8 per 100 tested; \u0026gt;=30 years, 69.9 per 100 tested. The CIR (ASR) during the study period: =\u0026lt; 4 years, 3 per 100 000 (14.5 per 100 000); 5-9 years, 2.5 per 100 000 (15.34 per 100 000); 9-14 years, 2 per 100 000(14.6 per 100 000); 15-29 years, 6.4 per 100 000(43.65 per 100 000); \u0026gt;=30 years, 4.2 per 100 000 (76.79) per 100 000). Furthermore, there was a pan age group increase in measles incidents from 2015 to 2018. See Table 2.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003ctable id=\"Tab2\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003eCrude incidence rate per 100,000, age adjusted incidence rates (ASR) per 1,000,000 and age specific positivity among 100 individuals the tested for measles in Eritrea, 2002\u0026ndash;2020\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth colspan=\"6\" align=\"left\"\u003e\n\u003cp\u003eCIR (ASR)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth colspan=\"8\" align=\"left\"\u003e\n\u003cp\u003eAge specific positivity rate per 100 tested\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eYear\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e=\u0026lt; 4\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e5\u0026ndash;9\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e9\u0026ndash;14\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e15\u0026ndash;29\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026gt;=30\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e=\u0026lt; 4\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e5\u0026ndash;9\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e9\u0026ndash;14\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e15\u0026ndash;29\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026gt;=30\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003eTotal\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2002\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.2 (.78)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.2(.77)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.04(.76)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.36(2.18)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.08(4.36)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e25\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e15.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e100\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e90\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e66.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e33.3\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2003\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.12(.59)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.47(1.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.63(1.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.59(4.42)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e30\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e70.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e69.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e83.3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e66.7\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2004\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.04(.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.11(.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.08(.29)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.08(.84)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.04(1.68)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e7.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e18.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e33.3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e100\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e100\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e23.7\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2005\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.07(.46)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.22(.45)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.15(1.27)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.07(2.54)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e7.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e15.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e66.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e66.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e15.7\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2006\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.07(.09)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.04(.09)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e4.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2.3\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2007\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2008\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2009\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.03(.09)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.03(.24)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.03(.49)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e50\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e100\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5.8\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2010\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.03(.14)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.1(.39)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.03(.79)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e33.3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e100\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2.9\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2011\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.03(.39)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.09(.38)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.03(.37)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.19(1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.09(2.15)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e2.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e4.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e31.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e50\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e9.5\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2012\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.27(3.19)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.12(3.13)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.06(3.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2(8.86)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.15(17.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e12.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e7.1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e9.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e61.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e78\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e39.3\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2013\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.06(1.22)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.06(1.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.15(1.19)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.76(3.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.35(6.81)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e5.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e33.3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e57.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e84.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e31.3\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2014\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.03(.03)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2015\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.14(2.24)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.28(2.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.17(2.17)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.94(6.22)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1(12.45)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e16.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e20.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e25\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e61.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e83.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e45.3\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2016\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.35(1.89)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.38(1.86)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.08(1.84)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.46(5.26)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.87(10.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e12.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e10.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e7.3\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e35.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e78\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e21.7\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2017\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.63(1.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.21(1.37)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.37(1.36)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.21(3.89)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.13(7.78)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e36.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e15.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e29.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e38.1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e55.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e30.3\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2018\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.67(1.59)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.18(1.56)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.26(1.54)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.41(4.41)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.26(8.83)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e44.1\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e22.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e35.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e43.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e50\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e39.4\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2019\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.1(.18)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.02(.17)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.05(.49)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e4.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e18.2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3.7\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2020\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.1(.28)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.02(.27)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.02(.27)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.07(.78)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.07(1.55)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e5.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e37.5\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e42.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e7.8\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eTotal\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e3(14.54)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2.5 (15.34)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2 (14.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6.4 (43.65)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e4.2 (77.69)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e11.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e8.6\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e17.4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e49.8\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e69.9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e21.5\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003eDefinitions: Attack rates \u003csub\u003eage specified\u0026nbsp;\u003c/sub\u003e= number of measles cases/number of people tested positive in that age group\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFactors associated with measles IgM positive febrile rash\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAmong the measles positive individuals\u0026rsquo; females account for 55% (n=334). The median age of positive individuals is higher than that of negative individuals (18 [7-29] vs 6 [3-10] years, Kruskal-Wallis test, p\u0026lt;0.001). The highest proportion of positives lie in the age group 15-29 years: 212 (35.1%) followed by more than 30 years 146 (24.2%), less than 4 years 102 (16.9%), 5-9 years 79 (13.1%), and 10-14 years 65 (10.8%), chi-square test p\u0026lt;0.001. Among the countries zones, a higher positivity was observed in the regions of NRS 145 (23.8%) and Anseba 142 (23.4%), chi-square p\u0026lt; 0.001. No apparent differences in the number of incidence cases by sex were observed (Table 1). Higher odds of MCV positivity were observed in Gash-Barka (OR=15.4(10.9-21.7), p\u0026lt;0.001), Southern Red Sea (OR=14.4 (8.2-25.2), p\u0026lt;0.001), Northern Red Sea (OR=11.8 (8.5-16.2), p\u0026lt;0.001), Debub (OR=2.7 (1.9-3.9), p\u0026lt;0.001) and Anseba (OR=2.3 (1.7-3.1), p\u0026lt;0.001) when compared to Maekel region. Hospitals\u0026rsquo; samples showed higher of odds of MCV positivity (224, 45.3%) when compared to health centers or stations, (OR=6.8 p\u0026lt;0.001, hospital vs health station). Higher odds of test positivity were also observed in unvaccinated individuals (OR=14.7 (11.4-19.1), p\u0026lt;0.001). See Table 3.\u003c/p\u003e\n\u003cdiv class=\"gridtable\"\u003e\n\u003ctable id=\"Tab3\" border=\"1\"\u003e\u003ccaption\u003e\n\u003cdiv class=\"CaptionNumber\"\u003eTable 3\u003c/div\u003e\n\u003cdiv class=\"CaptionContent\"\u003e\n\u003cp\u003eFactors associated with measles status in Eritrea, 2002\u0026ndash;2020\u003c/p\u003e\n\u003c/div\u003e\n\u003c/caption\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth rowspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eCharacteristics\u003c/p\u003e\n\u003c/th\u003e\n\u003cth colspan=\"3\" align=\"left\"\u003e\n\u003cp\u003eMeasles status\u003c/p\u003e\n\u003c/th\u003e\n\u003cth rowspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e\u003cem\u003ep\u003c/em\u003e-value (\u003cem\u003e\u0026chi;\u003c/em\u003e2)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth rowspan=\"2\" align=\"left\"\u003e\n\u003cp\u003eOR (95%CI)\u003c/p\u003e\n\u003c/th\u003e\n\u003cth rowspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e\u003cem\u003ep\u003c/em\u003e-value\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003ePositive (%)\u003c/strong\u003e\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003eNegative (%)\u003c/strong\u003e\u003c/p\u003e\n\u003c/th\u003e\n\u003cth align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003eIntermediate N (%)\u003c/strong\u003e\u003c/p\u003e\n\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"3\" align=\"left\"\u003e\n\u003cp\u003eGender\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eMale\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e267 (44.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e990 (48.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e50 (56.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.06 (5.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1(\u003cem\u003eRef.\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eFemale\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e334 (55.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1058 (51.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e38 (43.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.18 (.9-1.42)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.06\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eAge at onset of rash, median (IQR)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e18 (7\u0026ndash;29)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6 (3\u0026ndash;10)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e11 (5\u0026ndash;18)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;0.001\u003c/strong\u003e\u003csup\u003e\u003cstrong\u003ea\u003c/strong\u003e\u003c/sup\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e=\u0026lt;4\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e102(16.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e731 (35.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e18 (20.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"5\" align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;0.001 (645.7)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1(\u003cem\u003eRef.\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e5\u0026ndash;9\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e79 (13.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e805 (39)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e18 (20.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.7 (0.5\u0026ndash;0.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e0.02\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e10\u0026ndash;14\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e65 (10.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e274 (13.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e21 (24.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.6 (1.1\u0026ndash;2.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e0.005\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e15\u0026ndash;29\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e212 (35.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e203 (9.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e19 (21.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e7 (5.3\u0026ndash;9.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026gt;=30\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e146 (24.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e53 (2.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e11 (12.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e16.7 (11.7\u0026ndash;24)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"3\" align=\"left\"\u003e\n\u003cp\u003eAddress\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eMaekel\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e91 (15)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e962 (46.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e33 (37.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"6\" align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;0.001 (501.2)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1(\u003cem\u003eRef.\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eAnseba\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e142 (23.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e637 (30.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e24 (27.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2.3 (1.7\u0026ndash;3.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eDebub\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e64 (10.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e239 (11.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e13 (14.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2.7 (1.9\u0026ndash;3.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eGash-Barka\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e133 (21.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e90 (4.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e4 (4.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e15.4 (10.9\u0026ndash;21.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eNRS\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e145 (23.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e120 (5.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e13 (14.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e11.8 (8.5\u0026ndash;16.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eSRS\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e33 (5.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e24 (1.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1 (1.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e14.4 (8.2\u0026ndash;25.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"3\" align=\"left\"\u003e\n\u003cp\u003eHealth facility\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHealth station\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e90 (18.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e624 (47.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e22 (37.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"3\" align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;0.001 (198)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1(\u003cem\u003eRef.\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHealth center\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e180 (36.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e478 (36.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e23 (39)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2.5 (1.9\u0026ndash;3.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eHospital\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e224 (45.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e221 (16.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e14 (23.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e6.8 (5.1\u0026ndash;9.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"3\" align=\"left\"\u003e\n\u003cp\u003eVaccination status\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eAt least one dose\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e74 (12.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1380 (66.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e46 (52.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"3\" align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e(604.7)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1(\u003cem\u003eRef.\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eUnvaccinated\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e534 (87.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e654 (31.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e42 (47.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e14.7 (11.4\u0026ndash;19.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eUnknown\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e38 (1.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e-\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eLast vaccination\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2009 (2004\u0026ndash;2014)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2011 (2004\u0026ndash;2015)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2006 (2003\u0026ndash;2013)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e=\u0026lt;2009\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e34 (45.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e744 (54)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e31 (67.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e0.07 (5.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1(\u003cem\u003eRef.\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e=\u0026gt;2010\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e40 (54.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e635 (46)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e15 (32.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.4 (0.8\u0026ndash;2.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.15\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003eYear of onset of rash\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2012 (2010\u0026ndash;2017)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2015 (2012\u0026ndash;2016)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e2016 (2007\u0026ndash;2018)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e0.07\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e=\u0026lt;2014\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e287 (75.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1175 (91.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e36 (82.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"2\" align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e(72)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1(\u003cem\u003eRef.\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u0026gt;=2015\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e91 (24.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e104 (8.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e7 (17.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e1.4 (1.1\u0026ndash;1.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd align=\"left\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;\u0026thinsp;.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003c/div\u003e\n\u003cp\u003eAbbreviations: NRS: Northern Red Sea; SRS: Southern Red Sea; IQR: Interquartile Range.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFactors associated with measles vaccination\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIn the bivariate analysis, we demonstrated that unvaccinated individuals were older with a median age (IQR) of 9 (IQR: 1-25) years vs the vaccinated 3 (IQR: 3-8) years, Mann-Whitney U test p\u0026lt;0.001. Additionally, vaccination uptake was associated with age at the time of rash appearance, address, type of health facility, and year of onset of rash. Consequently, 276 (22.5%), 235 (19.26%), 150 (12.3%), 365 (29.8%) and 198(97.1%) of patients =\u0026lt;4 years, 5-9 years, 10-14 years, 15-29 years and \u0026gt;=30 years were not vaccinated. In the respective administrative zones, namely: Maekel, Anseba, Debub, Gash-Barka, NRS, and SRS; 270 (25.62%), 332 (41.4%), 153 (48.57%), 189 (84.00%), 232 (84.06%), 55 (94.83%) of patients presenting morbiliform rash were unvaccinated. Additionally, 228 (30.9%), 304 (44.7%) and 315 (66.63%) of patients with rashes in health stations, health centers and hospitals were not vaccined. Last but not least, =\u0026lt;2014 vs \u0026gt;=2015 analysis of = 2014 vs\u0026gt; = 2015 of the vaccination status of individuals who presented a rash indicated that 720 (49.38%) and 510 (40.13%) were not vaccined.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eIn the multivariate analysis, a high odd of being unvaccinated was associated with the age at onset of rash (1.11 (95% CI 1.10-1.13), p value\u0026lt;0.001); administrative zone (SRS: aOR=23(95% CI: 4.6-114), p value\u0026lt;0.001) (NRS: aOR=7.6 (95% CI: 4.6-12.7) (Anseba: aOR=2.4(95% CI: 1.8-3.2) (Debub: aOR=1.8 (95% CI: 1.2-2.6); and health facility (Health centre: 0.95 (95% CI: 0.72-1.3) (hospital: 5.1 (955 CI: 3.6 \u0026ndash; 7.2), p value\u0026lt; 0.001). Lastly, there was a notable association between year of rash onset and vaccination status (0.94 (95% CI: 0.90-0.99), p-value = 0.02). In other words, for each increase in year, there was a 6% increase in vaccination status of individuals with febrile rash (p=0.02).\u003c/p\u003e\n\u003ctable border=\"1\" width=\"886\" cellspacing=\"0\" cellpadding=\"0\"\u003e\u003ccaption\u003e\n\u003cp\u003eTable 4\u003c/p\u003e\n\u003cp\u003eFactors associated with measles vaccination among individuals with rash in Eritrea, 2002-2020\u003c/p\u003e\n\u003c/caption\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd rowspan=\"2\" width=\"17.13641488162345%\"\u003e\n\u003cp\u003e\u003cstrong\u003eCharacteristics\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"29.31228861330327%\"\u003e\n\u003cp\u003e\u003cstrong\u003eVaccination status\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"2\" width=\"10.4847801578354%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003ep\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e-value (\u003c/strong\u003e\u003cstrong\u003e\u003cem\u003e\u0026chi;\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e2\u003c/strong\u003e\u003cstrong\u003e)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"13.754227733934611%\"\u003e\n\u003cp\u003e\u003cstrong\u003eOR (95%CI)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"7.3280721533258175%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003ep\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e-value\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"6\" valign=\"top\" width=\"14.092446448703495%\"\u003e\n\u003cp\u003e\u003cstrong\u003eaOR (95%CI)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"7.891770011273957%\"\u003e\n\u003cp\u003e\u003cstrong\u003ep-value\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"2\" width=\"19.906687402799378%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAt least once (%)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"20.52877138413686%\"\u003e\n\u003cp\u003e\u003cstrong\u003eUnvaccinated (%)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"19.12908242612753%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"10.10886469673406%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"19.440124416796266%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"10.88646967340591%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"46.44870349492672%\"\u003e\n\u003cp\u003e\u003cstrong\u003eGender\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.4847801578354%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"13.754227733934611%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"3\" valign=\"top\" width=\"7.3280721533258175%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"6\" width=\"14.092446448703495%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"7.891770011273957%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"17.117117117117118%\"\u003e\n\u003cp\u003e\u003cstrong\u003eMale\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"14.414414414414415%\"\u003e\n\u003cp\u003e701 (54.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"14.864864864864865%\"\u003e\n\u003cp\u003e583 (45.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"2\" width=\"10.472972972972974%\"\u003e\n\u003cp\u003e0.8 (0.06)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"13.85135135135135%\"\u003e\n\u003cp\u003e1(\u003cem\u003eRef.\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"7.31981981981982%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"14.076576576576576%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"7.882882882882883%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"19.11949685534591%\"\u003e\n\u003cp\u003e\u003cstrong\u003eFemale\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"16.10062893081761%\"\u003e\n\u003cp\u003e780 (55.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.60377358490566%\"\u003e\n\u003cp\u003e636 (44.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"15.471698113207546%\"\u003e\n\u003cp\u003e0.9 (0.8-1.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"8.176100628930818%\"\u003e\n\u003cp\u003e0.7\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"15.723270440251572%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"8.80503144654088%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"17.13641488162345%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAge at onset of rash\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"14.430665163472378%\"\u003e\n\u003cp\u003e\u003cstrong\u003e3 (3-8)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"14.88162344983089%\"\u003e\n\u003cp\u003e\u003cstrong\u003e9 (1-25)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"10.4847801578354%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"13.754227733934611%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"7.3280721533258175%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"5\" width=\"14.092446448703495%\"\u003e\n\u003cp\u003e1.11 (1.10-1.13)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"7.891770011273957%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"17.117117117117118%\"\u003e\n\u003cp\u003e\u003cstrong\u003e=\u0026lt;4\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"14.414414414414415%\"\u003e\n\u003cp\u003e563 (67.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"14.864864864864865%\"\u003e\n\u003cp\u003e276 (22.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"5\" width=\"10.472972972972974%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001 (686.5)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"13.85135135135135%\"\u003e\n\u003cp\u003e1(\u003cem\u003eRef.\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"7.31981981981982%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"14.076576576576576%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"7.882882882882883%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"19.11949685534591%\"\u003e\n\u003cp\u003e\u003cstrong\u003e5-9\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"16.10062893081761%\"\u003e\n\u003cp\u003e661 (44.20\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.60377358490566%\"\u003e\n\u003cp\u003e235 (19.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"15.471698113207546%\"\u003e\n\u003cp\u003e0.7 (0.5-0.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"8.176100628930818%\"\u003e\n\u003cp\u003e\u003cstrong\u003e0.002\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"15.723270440251572%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"8.80503144654088%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"19.11949685534591%\"\u003e\n\u003cp\u003e\u003cstrong\u003e10-14\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"16.10062893081761%\"\u003e\n\u003cp\u003e206 (13.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.60377358490566%\"\u003e\n\u003cp\u003e150 (12.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"15.471698113207546%\"\u003e\n\u003cp\u003e1.4 (1.1-1.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"8.176100628930818%\"\u003e\n\u003cp\u003e\u003cstrong\u003e0.002\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"15.723270440251572%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"8.80503144654088%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"19.11949685534591%\"\u003e\n\u003cp\u003e\u003cstrong\u003e15-29\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"16.10062893081761%\"\u003e\n\u003cp\u003e61 (4.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.60377358490566%\"\u003e\n\u003cp\u003e365 (29.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"15.471698113207546%\"\u003e\n\u003cp\u003e12.2 (8.9-16.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"8.176100628930818%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"15.723270440251572%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"8.80503144654088%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"19.11949685534591%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026gt;=30\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"16.10062893081761%\"\u003e\n\u003cp\u003e6 (2.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.60377358490566%\"\u003e\n\u003cp\u003e198 (97.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"15.471698113207546%\"\u003e\n\u003cp\u003e67.3 (29.5-153.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"8.176100628930818%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"15.723270440251572%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"8.80503144654088%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"46.44870349492672%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAddress\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"10.4847801578354%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"13.754227733934611%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"3\" valign=\"top\" width=\"7.3280721533258175%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"6\" width=\"14.092446448703495%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"7.891770011273957%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"17.117117117117118%\"\u003e\n\u003cp\u003e\u003cstrong\u003eMaekel\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"14.414414414414415%\"\u003e\n\u003cp\u003e784 (74.38)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"14.864864864864865%\"\u003e\n\u003cp\u003e270 (25.62)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"6\" width=\"10.472972972972974%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt; 0.001 (532.2)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"13.85135135135135%\"\u003e\n\u003cp\u003e1(\u003cem\u003eRef.\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"7.31981981981982%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"14.076576576576576%\"\u003e\n\u003cp\u003e1(\u003cem\u003eRef.\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"7.882882882882883%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"19.11949685534591%\"\u003e\n\u003cp\u003e\u003cstrong\u003eAnseba\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"16.10062893081761%\"\u003e\n\u003cp\u003e470 (58.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.60377358490566%\"\u003e\n\u003cp\u003e332 (41.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"15.471698113207546%\"\u003e\n\u003cp\u003e2 (1.6-2.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"8.176100628930818%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"15.723270440251572%\"\u003e\n\u003cp\u003e2.4 (1.8-3.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"8.80503144654088%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"19.11949685534591%\"\u003e\n\u003cp\u003e\u003cstrong\u003eDebub\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"16.10062893081761%\"\u003e\n\u003cp\u003e162 (51.43)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.60377358490566%\"\u003e\n\u003cp\u003e153 (48.57)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"15.471698113207546%\"\u003e\n\u003cp\u003e2.7 (2.1-3.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"8.176100628930818%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"15.723270440251572%\"\u003e\n\u003cp\u003e1.8 (1.2-2.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"8.80503144654088%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"19.11949685534591%\"\u003e\n\u003cp\u003e\u003cstrong\u003eGash-Barka\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"16.10062893081761%\"\u003e\n\u003cp\u003e36 (16.0)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.60377358490566%\"\u003e\n\u003cp\u003e189 (84.00)\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"15.471698113207546%\"\u003e\n\u003cp\u003e15.2 (10.4-22.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"8.176100628930818%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"15.723270440251572%\"\u003e\n\u003cp\u003e10.9 (6.1-19.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"8.80503144654088%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"19.11949685534591%\"\u003e\n\u003cp\u003e\u003cstrong\u003eNRS\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"16.10062893081761%\"\u003e\n\u003cp\u003e44 (15.94)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.60377358490566%\"\u003e\n\u003cp\u003e232 (84.06)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"15.471698113207546%\"\u003e\n\u003cp\u003e15.3 (10.7-21.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"8.176100628930818%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"15.723270440251572%\"\u003e\n\u003cp\u003e7.6 (4.6-12.7)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"8.80503144654088%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"19.11949685534591%\"\u003e\n\u003cp\u003e\u003cstrong\u003eSRS\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"16.10062893081761%\"\u003e\n\u003cp\u003e3 (5.17)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.60377358490566%\"\u003e\n\u003cp\u003e55 (94.83)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"15.471698113207546%\"\u003e\n\u003cp\u003e53.2 (16.5-171.5)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"8.176100628930818%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"15.723270440251572%\"\u003e\n\u003cp\u003e23 (4.6-114)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"8.80503144654088%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"46.44870349492672%\"\u003e\n\u003cp\u003e\u003cstrong\u003eHealth facility\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"10.4847801578354%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"13.754227733934611%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"3\" valign=\"top\" width=\"7.3280721533258175%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"6\" width=\"14.092446448703495%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"7.891770011273957%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"17.117117117117118%\"\u003e\n\u003cp\u003e\u003cstrong\u003eHealth station\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"14.414414414414415%\"\u003e\n\u003cp\u003e509 (69.1)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"14.864864864864865%\"\u003e\n\u003cp\u003e228 (30.9)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd rowspan=\"3\" width=\"10.472972972972974%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt; 0.001 (162.3)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"13.85135135135135%\"\u003e\n\u003cp\u003e1(\u003cem\u003eRef.\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"7.31981981981982%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"14.076576576576576%\"\u003e\n\u003cp\u003e1(\u003cem\u003eRef.\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"7.882882882882883%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"19.11949685534591%\"\u003e\n\u003cp\u003e\u003cstrong\u003eHealth center\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"16.10062893081761%\"\u003e\n\u003cp\u003e337 (52.6)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.60377358490566%\"\u003e\n\u003cp\u003e304 (47.4)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"15.471698113207546%\"\u003e\n\u003cp\u003e1.8 (1.4-2.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"8.176100628930818%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"15.723270440251572%\"\u003e\n\u003cp\u003e0.95 (0.72-1.3)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"8.80503144654088%\"\u003e\n\u003cp\u003e0.7\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"19.11949685534591%\"\u003e\n\u003cp\u003e\u003cstrong\u003eHospital\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"16.10062893081761%\"\u003e\n\u003cp\u003e144 (31.37)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.60377358490566%\"\u003e\n\u003cp\u003e315 (68.63)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"15.471698113207546%\"\u003e\n\u003cp\u003e4.8 (3.7-6.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"5\" valign=\"top\" width=\"8.176100628930818%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"15.723270440251572%\"\u003e\n\u003cp\u003e5.1 (3.6-7.2)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"8.80503144654088%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"17.13641488162345%\"\u003e\n\u003cp\u003e\u003cstrong\u003eYear of onset of rash\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" width=\"14.430665163472378%\"\u003e\n\u003cp\u003e2015 (2010-2017)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"14.88162344983089%\"\u003e\n\u003cp\u003e2013 (2010-2016)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"10.4847801578354%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003csup\u003ea\u003c/sup\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"13.754227733934611%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"4\" valign=\"top\" width=\"7.3280721533258175%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"13.528748590755356%\"\u003e\n\u003cp\u003e0.94 (0.90-0.99)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"8.455467869222097%\"\u003e\n\u003cp\u003e\u003cstrong\u003e0.02\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"17.175141242937855%\"\u003e\n\u003cp\u003e\u003cstrong\u003e=\u0026lt;2014\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"14.124293785310735%\"\u003e\n\u003cp\u003e738 (50.62)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"15.141242937853107%\"\u003e\n\u003cp\u003e720 (49.38)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" rowspan=\"2\" width=\"10.734463276836157%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001 (15.8)\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"14.689265536723164%\"\u003e\n\u003cp\u003e1(\u003cem\u003eRef.\u003c/em\u003e)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"6\" width=\"8.248587570621469%\"\u003e\u0026nbsp;\u003c/td\u003e\n\u003ctd colspan=\"3\" width=\"14.124293785310735%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"5.762711864406779%\"\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr\u003e\n\u003ctd valign=\"top\" width=\"19.19191919191919%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026gt;=2015\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"2\" valign=\"top\" width=\"16.161616161616163%\"\u003e\n\u003cp\u003e761 (59.87)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd valign=\"top\" width=\"16.666666666666668%\"\u003e\n\u003cp\u003e510 (40.13)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"3\" valign=\"top\" width=\"16.54040404040404%\"\u003e\n\u003cp\u003e0.6 (0.5-0.8)\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"8.207070707070708%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026lt;0.001\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd colspan=\"4\" width=\"15.782828282828282%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003ctd width=\"7.44949494949495%\"\u003e\n\u003cp\u003e\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eAbbreviations\u003c/strong\u003e: NRS: Northern Red Sea; SRS: Southern Red Sea; IQR: Interquartile Range.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSpatial distribution of measles tests and positive cases from 2002-2020 across Eritrean sub-zones\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eFigure 2 (A-D) presents the distribution of measles by quantiles of the number of serologic tests (T) and positive (P) results in Eritrea from 2002 \u0026ndash; 2020. On the main, the figures demonstrate that measles testing is highly heterogeneous and is mostly concentrated in subzones around Maekel (central administrative district) where the testing laboratory is located. Furthermore, between 2017 and 2020, testing in some of the most vulnerable regions was low.\u003c/p\u003e"},{"header":"Discussion ","content":"\u003cp\u003eIn an era where measles elimination is increasingly becoming a reality even in countries in some of the most disadvantaged parts of the world; sound evidence on incidence, trends, and associated factors at the national and rural level is essential. The current exploratory study aims to investigate these themes in Eritrea. In each and every one of these domains, we discovered multiple standout features. Foremost is the fact that the incidence of measles in Eritrea undulated between moderate to low rate periods over the course of 18 years. Highest CIR \u0026gt; 1 per 100 000 were reported in 2003 (1.79 per 100 000); 2012 (3.6 per 100 000); 2013 (1.38 per 100 000); 2015 (2.52 per 100 000); 2016 (2.14 per 100 000); 2016 (2.13 per 100 000); 2017 (1.58 per 100 000); and 2018 (1.79 per 100 000). These results are in line with data from a recent study on progress towards measles elimination in Eritrea: 2003 \u0026ndash; 2018 (8). Importantly, estimates are relatively lower than what has been reported in the African region (567 per 1 million) (15).\u003c/p\u003e\n\u003cp\u003eIn a recent work modelling the so-called canonical path to measles elimination, Graham and colleagues argued that in most countries; the path to elimination is tripartite. It begins with regime of uncontrolled endemic transmission regime, characterised by a high incidence of measles and low year-to-year variability. This progresses to a second phase characterised by low incidence but high variability. The final phase is that of the elimination state, i.e. zero incidence and zero variability (16). Based on our data, we can conclude that Eritrea is in the second stage of the canonical path. Indeed, our analysis appears to show that Eritrea has a relatively low incidence of MCV with a high year-to-year variability. In a separate analysis, we demonstrate that Eritrea has lingered in this stage for a relatively long time.\u003c/p\u003e\n\u003cp\u003eAlthough the present analysis provides a lot of insight on the state of measles elimination efforts in Eritrea, the problem of data reliability should be acknowledged. Indeed, the likelihood that this study has underestimated the incidence of measles in the country is hard to discount. Unlike the Yahdego \u003cem\u003eet al.\u003c/em\u003e study which estimated measles incidence based on cases confirmed by laboratory, epidemiological linkage, and clinical criteria (i.e., as if the country is in the pre-elimination phase); our study relied entirely on laboratory confirmed cases. Adoption of this approach was based on the fact that clinical case definition has a limited role in measles case classification in some pre-elimination settings. In other words, the likelihood that measles-like rash symptoms are due to other diseases like Scarlet fever, Rubella, Epstein-Barr virus, Parvovirus B19 Infection (Fifth disease), Chikungunya, and Dengue virus (which are increasingly affecting these populations) is high in some settings. Although outbreaks of Dengue virus, Rubella, and Chikungunya have been reported in Neighboring countries, data from Eritrea is limited. Therefore, the contribution to notified cases is hard to discern.\u003c/p\u003e\n\u003cp\u003eAdditionally, we are aware that the exclusive use of laboratory confirmed cases in estimating the incidence of measles incidence in recent years is severely undermined by suboptimal tests of suspected cases. With the exception of 2003, the frequency of serological tests was higher (Minimum 71.23% - Maximum, 100%) prior to 2012; a sharp decline was observed in the subsequent years. In 2017 for instance, the testing frequency of suspected cases reached a nadir of 6.22%. Taking all this into account (even the possibility that a substantial number of suspected cases were due to other causes), the possibility that our study has underestimated the true incidence of measles is substantial. The underreporting of measles can also be attributed to existing surveillance methods. In general, measles surveillance in WHO-AFR is largely based on passive surveillance (based on hospital admissions or contact). In areas where access to hospital or other care facilities is compromised by sub-optimal awareness, poor health seeking behaviour, long distances to facilities, vaccine hesitancy, self-medication, and use of alternative medicine; under-reporting of measles cases is inevitable. As such, reported cases reflect a small proportion of the actual case burden in most countries in WHO-AFR (17).\u003c/p\u003e\n\u003cp\u003eIn recent years, potential underreporting of measles cases has been investigated by multiple authors with remarkable results. For example, in the a study conducted in Oromia region in Ethiopia, Poletti \u003cem\u003eet al.\u003c/em\u003e reported that the effectiveness of passive surveillance based on hospital admissions or contact decreases dramatically with travel distances from the hospital, becoming negligible beyond 20 - 30 km from the hospital (18). In Kenya, a differently themed study established that admission rates decreased by 11 - 20% per 5-km increase in distance from a care facility (19). In Figure 1, we demonstrated a strong bias in the distribution of health facilities particularly in regions bordering Sudan, Ethiopia, and Djibouti. It should be noted that all these countries have suboptimal MCV coverage \u0026ndash; Ethiopia (MCV1 = 59% and MCV2 9% in 2019 (20); Sudan (MCV1 = 90% and MCV2 =72% in 2017) (20), and Djibouti (MCV1=72% and MCV2=82% in 2016) (15). Collectively, the true incidence of measles in hard-to-reach communities that border these countries is hard to gauge.\u003c/p\u003e\n\u003cp\u003eAs progress is made toward elimination of measles, knowledge of age distribution patterns in local populations can be crucial for targeted MCV campaigns (16). In this analysis, the age-based analysis of CIR and ASR revealed that measles cases were higher in adolescents and adults. Among the 608 (21.9%) laboratory confirmed cases, 53(9.92%) were \u0026lt;1-year-old. This finding corroborates previous reports that suggested that the median age for measles susceptibility is high and that measles incidence is largely driven by susceptible adolescents and adults (8). According to Prada and colleagues, the achievement of the required MCV thresholds can have a dual impact on the epidemiology of measles \u0026ndash; it can lengthen the inter-epidemic period and increase the average / or median age at infection (21).The epidemiological shift to older cohorts is therefore an indicator of progress. From a policy perspective, the data suggests that SIA targeting children from 9 months to 14 years of age (as was the case in 2003-2018) (8) will not reach a significant number of susceptible individuals. \u003c/p\u003e\n\u003cp\u003eThe scaling of the measles distribution with age has been linked to multiple factors. First, the distribution of measles can be influenced by birth rates and overall age structure (16). Obviously, high birth rates will skew incidence towards younger cohorts \u0026ndash; the converse also applies. Furthermore, we must note the fact that annual vaccine coverage reports in WHO repositories do not involve all age groups. The focus of these reports is mostly restricted to infants. Consequently, WHO country reports often ignore the possible ways in which age-related factors, such as suboptimal vaccination in previous ears (say 20 years ago), vaccine failure (primary or secondary) (22), and temporal variations in vaccine effectiveness or quality, can undermine herd immunity thresholds (23). In Eritrea, for example, MCV1 coverage in 1993 was 34% and sustained MCV1 coverage \u0026gt; 95% was achieved in 2003 (8). Importantly, routine coverage of MCV2 was initiated in 2012 and required thresholds (\u0026gt; 85%) have not been met. Based on these reports, we can conclude that a significant number of young adults and adolescents were either unvaccinated or under vaccinated. Therefore, the increased susceptibility to measles in adolescents and young adults observed in this setting aligns with expectation. This determination is broadly supported by the result showing an 89% decrease in the likelihood of being vaccinated per year of age increase. \u003c/p\u003e\n\u003cp\u003eFurthermore, the possibility that population level of the population may not be as high as the coverage data suggest was recently demonstrated by a study carried out on a small population of Eritreans abroad (average age: 25 years). In this study, the researchers demonstrated that only 76.4% of the study participants had the required concentration of protective antibody titers for measles (24). A different study placed the figure at a marginally higher proportion, 79.9% (25). Together, our data suggest (at least partly) that residual susceptibility inherited from the underperformance of vaccination campaigns (MCV2 in particular (26) in the past decades continues to undermine measles elimination efforts. Therefore, the need for serological surveys (a direct measure of immunity) and more frequent catch-up and follow-up campaigns targeting unvaccinated adolescents and young adults living in rural, hard-to-reach communities is warranted.\u003c/p\u003e\n\u003cp\u003eFurther stand-out features of our results include low mortality rates, potential improvements in case notification efficiency, and as previously noted (8); gaps in surveillance performance, particularly, laboratory analysis of suspected cases and epidemiological investigations. In general, much of the discussion on the short-comings of passive surveillance applies to data on measles case fatality rates (CFR). Regarding measles surveillance, we noted a significant under-performance in the laboratory investigation of suspected cases of measles in recent years. The spatial analysis demonstrated a disjunction between regions with higher test rates and regions with measles induced rash. In other words, regions with high prevalence of measles-like symptoms were under-tested. For example, from 2017 to 2020, suspected cases from regions bordering regions (Zone 1 and Zone 2 in the Afar region in Ethiopia) with some of the lowest coverage of MCV1 and MCV2 vaccine coverage (~29.6%) (27, 28) and high incidence of measles in Ethiopia were not tested. Similarly, regions neighbouring Sudan or Djibouti are either under-tested or not tested. Altogether, our results are in line with a previous study in Eritrea which indicated that the country has not attained the 80% target for reporting suspected measles cases with blood specimen since 2011(8). Other investigators in the region have reported similar degeneration in measles surveillance (29).\u003c/p\u003e\n\u003cp\u003eAccording to the WHO, suspected measles cases should be confirmed in the laboratory using serological tests or Nucleic Acid based tests (RT-PCR). This requirement is based on the assumption that the positive predictive value (PPV) of clinical case definition is low in settings with a low incidence of measles. The problem of low PPV can be compounded by the high prevalence of viruses that can cause morbiliform rashes (30). As noted earlier, the official WHO-UNICEF or WHO Eritrea Biennium Report 2020-2021 (31) suggest that the incidence of measles in Eritrea is low and the prevalence of viruses that can cause measles-like rashes is growing; therefore, comprehensive case investigation, documentation, and reporting is essential. Another allied concern was the observed discrepancy in the number of suspected cases of measles documented in IDSR and the numbers reported in the official WHO-UNICEF Joint Reporting Form (JRF). As noted previously, the discrepancy points to gaps in reporting and the need for data harmonization.\u003c/p\u003e\n\u003cp\u003eIn a separate analysis, we investigated the epidemiology of laboratory confirmed measles cases. According to our analysis, the diagnosis of measles was associated with age, address, facility type, vaccination status, and year of the onset of rash. In the logistic regression analysis, we showed that children \u0026lt; 5 \u0026ndash; 9 years had a lower likelihood of measles-like rash compared to children \u0026lt; 4 years. This finding is supported by previous research (16) and has been linked to the age of eligibility for MCV. In general, MCV1 is given at 9 months in Eritrea. Therefore, a significant number of children \u0026lt; 1 years are unvaccinated and are thus susceptible to measles. Based on recent trends in MCV coverage, a lower frequency of measles in children aged 5-9 years. As noted previously, the significant age-dependent increase in the likelihood of measles-like rash in individuals \u0026gt; 10 years is probably related to underperformance of vaccination campaigns in the past.\u003c/p\u003e\n\u003cp\u003eSimilar to other studies in the region (32), we observed a significant geographical variation in the likelihood of test positivity. Predictably, the likelihood of test positivity was lower in Maekel; the zone where testing is concentrated and vaccine coverage is higher. Regions bordering Sudan (Gash-Barka and NRS) and Ethiopia and Djibouti (SRS) had the highest likelihood of test positivity (and low testing density as noted earlier). Remarkably, SRS which borders regions in Ethiopia with extremely low vaccination coverage (Afar region \u0026ndash; Zone 1 and Zone 2 have vaccine coverage \u0026lt;30%) (27, 28); had the highest likelihood of measles test positivity. Furthermore, NRS and Gash-Barka, which border administrative regions in Sudan (Red Sea and Kasala), which have relatively frequent measles outbreaks (33); had a high number of patients with measles-like rash, high test positivity, and low number of tests. Compared to Maekel, the likelihood of being unvaccinated in these regions was relatively high. A similar finding was reported in a previous study (26). Previously, we suggested that parts of NRS, Gash Barka, and SRS have relatively low density of health infrastructure and that this can lead to spatial inequalities in routine vaccine coverage or testing. Another factor that can undermine vaccine coverage in these settings is that fact that some communities living in these regions have nomadic and semi-nomadic lifestyle. \u003c/p\u003e\n\u003cp\u003eAlthough our analysis has shown a higher measles positivity rate in patients with measles-like rash in NRS, Gash Barka, SRS, and the presence of a host of factors that can undermine measles vaccine coverage, testing or reporting; we are not suggesting that measles may be endemic in these regions. Previous mathematical calculations addressing the epidemiology of measles have shown that a population of 250,000 to 500,000 people is required to establish measles as an endemic disease (16). In contrast, NRS and SRS are sparsely populated and settlements are relatively isolated, suggesting that measles outbreaks are largely due to persistent reintroduction from other areas. Furthermore, social contact clusters in these regions often cut across national borders. This concern was recently reiterated in a WHO report suggesting that despite high measles vaccines in Eritrea, the country is at risk of measles importation due to cross-border population movement and potential population mix dynamics (31). Additional support for this conclusion is related to the fact that the impact of low vaccination coverage and the endemicity of measles in surrounding countries is known to be more pronounced in smaller countries like Eritrea (16). However, in the absence of realistic data on social mixing patterns in cross-border communities and genotypic data; tracking of the sources of outbreaks or transmission chains in the country is difficult. In summary, we conclude that even if the conditions for the elimination of measles elimination (MCV1 \u0026gt;95% and MCV2 \u0026gt; 85% in all regions) are met in Eritrea; sustained elimination will be difficult due to the high odds of transmission across the border from highly impacted, under-vaccinated sub-regions in Sudan and Ethiopia. Therefore, the importance of regional coordination of elimination efforts and robust surveillance in NRS, SRS, and Gash-Barka cannot be overemphasised. \u003c/p\u003e\n\u003cp\u003eLast but not least, we showed that patients in hospitals had a higher probability of test positivity compared to patients from health centres / stations. A plausible explanation for this finding relates to the possibility that patients with measles-related complications are usually referred by primary health clinics (PHC) to hospitals where trained physicians are stationed. Unlike caregivers in PHCs; physicians in hospitals may be better at diagnosis and profiling. Separately, we found a connection between measles test positivity and vaccination. This outcome is supported by previous studies done in Ethiopia (18, 34), South Sudan\u003cspan dir=\"RTL\"\u003e \u003c/span\u003e(35), and Gambia (32). Interestingly, individuals who were vaccinated before 2010 had a higher likelihood of measles test positivity. At present, we have no obvious explanation for this outcome. However, we believe that the proximity between this timeline and the initiation of MCV2 coverage in 2012 is not coincidental. \u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStrength and Limitation \u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eUnlike previous work which utilized data from WHO/UNICEF Joint Reporting Form (JRF) and administrative data, we sourced our data from the national and sub-national representative DHS database. This notwithstanding, our study suffers from a number of limitations including inconsistencies in measles testing between subregions and over time. Additionally, information on vaccination status was based, to a large extent, on self-reported responses. Therefore, social desirability bias cannot be discounted. Last but not least, retrospective studies typically suffer from missing data problems, and we believe that this study was not an exception. \u003c/p\u003e"},{"header":"Conclusion ","content":"\u003cp\u003eOur report suggests that Eritrea has a relatively low incidence of measles but a high variability year-to-year. However, the potential for under-estimation of cases exists due to under-reporting of suspected cases and incomplete testing, particularly in recent years. Furthermore, age-based analysis of CIR and ASR revealed that the median age for measles cases was 7 years (IQR: 4-14 years). This means that SIV campaigns targeting individuals \u0026lt; 14 years will miss a large proportion of individuals with residual susceptibility. Laboratory positivity for measles was associated with increasing age, residence in border regions (Gash-Barka, SRS, and NRS), level of care facility, vaccination status, and year of onset of measles-like rash. Interestingly, uptake of MCV was associated with a similar complement of factors. In a separate analysis, we demonstrated that despite the high coverage of MCV in Eritrea, spatial inequalities in vaccine coverage or surveillance and extremely low vaccination rates in specific subregions in neighboring countries continue to undermine elimination efforts. To address these issues, there should be more focus on regional microplanning to create efficient systems for monitoring, reporting, and management of outbreaks. Additional strategies can include decentralisation of testing; targeted serological surveys; ring vaccination in border areas; more frequent catch-up SIAs targeting unvaccinated adults and adolescents; building capacity for genetic testing of isolates, and enhancing regional coordination of elimination efforts.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eFunding:\u0026nbsp;\u003c/strong\u003eThis research received no external funding.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInstitutional Review Board Statement\u003c/strong\u003e: The study was carried out according to the Declaration of Helsinki and was approved by Ethical Committee of the Eritrean Ministry of Health. Written consent was not obtained from the patients. Instead, the data was de-identified and all ethical and professional considerations undergirding confidentiality/or others protections of patient information were rigorously implemented.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eData Availability Statement\u003c/strong\u003e: Data are not publicly available due to privacy and confidentiality. Restrictions apply to the availability of data, but are available for the authors with the permission of the organisation.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConflicts of Interest\u003c/strong\u003e: The authors declare no conflict of interest.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contribution:\u003c/strong\u003e S.T.M. conceived and designed the study. S.T.M., A.T.T., F.T., I.M., M.S., D.F., H.A., R.M., T.T., and L.G.W. participated in the performed data collection. S.T.M., and O.O.A. did the statistical analysis and spatial mapping. STM, O.O.A., M.E.H., and W.Y.W. did the data presentation, and reviewed/edited the manuscript. All authors read and approved the final manuscript.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003eLaksono BM, de Vries RD, McQuaid S, Duprex WP, de Swart RL. Measles Virus Host Invasion and Pathogenesis. Viruses. 2016 Jul 28;8(8). eng. Epub 2016/08/03. doi:10.3390/v8080210. Cited in: Pubmed; PMID 27483301.\u003c/li\u003e\n \u003cli\u003ede Vries RD, Duprex WP, de Swart RL. Morbillivirus infections: an introduction. Viruses. 2015 Feb 12;7(2):699-706. eng. Epub 2015/02/17. doi:10.3390/v7020699. Cited in: Pubmed; PMID 25685949.\u003c/li\u003e\n \u003cli\u003eFactsheet W. Measles. 2023 3 May. Available from: https://www.who.int/news-room/fact-sheets/detail/measles.\u003c/li\u003e\n \u003cli\u003eWang R, Jing W, Liu M, Liu J. Trends of the global, regional, and national incidence of measles, vaccine coverage, and risk factors in 204 countries from 1990 to 2019. Frontiers in Medicine. 2022;8:2885.\u003c/li\u003e\n \u003cli\u003eThompson KM. What will it take to end human suffering from measles? The Lancet Infectious Diseases. 2017;17(10):1013-1014.\u003c/li\u003e\n \u003cli\u003eMoss WJ, Shendale S, Lindstrand A, O\u0026apos;Brien KL, Turner N, Goodman T, Kretsinger K. Feasibility assessment of measles and rubella eradication. Vaccine. 2021;39(27):3544-3559.\u003c/li\u003e\n \u003cli\u003eOrganisation WH. Regional Committee for Africa. Measles elimination by 2020: a strategy for the African Region. 2020 4 May. Available from: https://www.afro.who.int/sites/default/files/sessions/working_documents/AFR-RC61-8-Measles-elimination-by-2020---strategy-forthe-African-Region---with-Resolution.pdf.\u003c/li\u003e\n \u003cli\u003eYehdego T, Yhdego TK, Masresha B, Gebreslassie A, Katsande R, Fussum D, Lebo E, Namboze J. Progress towards measles elimination in Eritrea: 2003 - 2018. Pan Afr Med J. 2020;35(Suppl 1):7. eng. Epub 2020/05/07. doi:10.11604/pamj.supp.2020.35.1.19126. Cited in: Pubmed; PMID 32373258.\u003c/li\u003e\n \u003cli\u003eMasresha BG, Kaiser R, Eshetu M, Katsande R, Luce R, Fall A, Dosseh AR, Naouri B, Byabamazima CR, Perry R, Dabbagh AJ, Strebel P, Kretsinger K, Goodson JL, Nshimirimana D. Progress toward measles preelimination--African Region, 2011-2012. MMWR Morb Mortal Wkly Rep. 2014 Apr 4;63(13):285-91. eng. Epub 2014/04/05. Cited in: Pubmed; PMID 24699765.\u003c/li\u003e\n \u003cli\u003eOrganization WH. World health statistics 2018: monitoring health for the SDGs, sustainable development goals. World Health Organization; 2018. ISBN: 9241565586.\u003c/li\u003e\n \u003cli\u003eOrganization WH. African regional guidelines for measles and rubella surveillance. African Regional guidelines for measles and rubella surveillance-Draft version April. 2015.\u003c/li\u003e\n \u003cli\u003eGetahun M, Beyene B, Ademe A, Teshome B, Tefera M, Asha A, Afework A, HaileMariyam Y, Assefa E, Gallagher K. Epidemiology of laboratory confirmed measles virus cases in Amhara Regional State of Ethiopia, 2004\u0026ndash;2014. BMC infectious diseases. 2016;16(1):1-7.\u003c/li\u003e\n \u003cli\u003eMitiku K, Bedada T, Masresha BG, Kegne W, Nafo-Traor\u0026eacute; F, Tesfaye N, Yigzaw A. Progress in measles mortality reduction in Ethiopia, 2002-2009. J Infect Dis. 2011 Jul;204 Suppl 1:S232-8. eng. Epub 2011/06/17. doi:10.1093/infdis/jir109. Cited in: Pubmed; PMID 21666166.\u003c/li\u003e\n \u003cli\u003eOffice NS. Eritrea Demographic and Health Survey 1995 1997 4 May. Available from: https://dhsprogram.com/pubs/pdf/FR80/FR80.pdf.\u003c/li\u003e\n \u003cli\u003ePatel MK, Goodson JL, Alexander JP, Jr., Kretsinger K, Sodha SV, Steulet C, Gacic-Dobo M, Rota PA, McFarland J, Menning L, Mulders MN, Crowcroft NS. Progress Toward Regional Measles Elimination - Worldwide, 2000-2019. MMWR Morb Mortal Wkly Rep. 2020 Nov 13;69(45):1700-1705. eng. Epub 2020/11/13. doi:10.15585/mmwr.mm6945a6. Cited in: Pubmed; PMID 33180759.\u003c/li\u003e\n \u003cli\u003eGraham M, Winter AK, Ferrari M, Grenfell B, Moss WJ, Azman AS, Metcalf CJE, Lessler J. Measles and the canonical path to elimination. Science. 2019;364(6440):584-587.\u003c/li\u003e\n \u003cli\u003eJani JV, Jani IV, Ara\u0026uacute;jo C, Sahay S, Barreto J, Bjune G. Assessment of routine surveillance data as a tool to investigate measles outbreaks in Mozambique. BMC infectious diseases. 2006;6:1-9.\u003c/li\u003e\n \u003cli\u003ePoletti P, Parlamento S, Fayyisaa T, Feyyiss R, Lusiani M, Tsegaye A, Segafredo G, Putoto G, Manenti F, Merler S. The hidden burden of measles in Ethiopia: how distance to hospital shapes the disease mortality rate. BMC Med. 2018 Oct 18;16(1):177. eng. Epub 2018/10/20. doi:10.1186/s12916-018-1171-y. Cited in: Pubmed; PMID 30333039.\u003c/li\u003e\n \u003cli\u003eManakongtreecheep K, Davis R. A review of measles control in Kenya, with focus on recent innovations. Pan Afr Med J. 2017;27(Suppl 3):15. eng. Epub 2018/01/04. doi:10.11604/pamj.supp.2017.27.3.12118. Cited in: Pubmed; PMID 29296150.\u003c/li\u003e\n \u003cli\u003eYehualashet DE, Seboka BT, Tesfa GA, Mamo TT, Seid E. Determinants of optimal antenatal care visit among pregnant women in Ethiopia: a multilevel analysis of Ethiopian mini demographic health survey 2019 data. Reproductive Health. 2022;19(1):1-8.\u003c/li\u003e\n \u003cli\u003eFerrari MJ, Grenfell BT, Strebel PM. Think globally, act locally: the role of local demographics and vaccination coverage in the dynamic response of measles infection to control. Philos Trans R Soc Lond B Biol Sci. 2013 Aug 5;368(1623):20120141. eng. Epub 2013/06/27. doi:10.1098/rstb.2012.0141. Cited in: Pubmed; PMID 23798689.\u003c/li\u003e\n \u003cli\u003eMoss W. Measles in vaccinated individuals and the future of measles elimination. Oxford University Press US; 2018. p. 1320-1321.\u003c/li\u003e\n \u003cli\u003ePreeta Kutty JR, William Bellini, Susan B. Redd, Albert Barskey, Wallace G. Vaccine-Preventable Diseases Surveillance Manual: Measles: CDC; 2013. . 2013 5 May. Available from: http://www.cdc.gov/vaccines/pubs/surv-manual/chpt07-measles.pdf.\u003c/li\u003e\n \u003cli\u003eStaehelin C, Chernet A, Sydow V, Piso RJ, Suter-Riniker F, Funez S, Nickel B, Paris DH, Labhardt ND. Seroprotection rates of vaccine-preventable diseases among newly arrived Eritrean asylum seekers in Switzerland: a cross-sectional study. Journal of travel medicine. 2019;26(6):taz035.\u003c/li\u003e\n \u003cli\u003eCeccarelli G, Vita S, Riva E, Cella E, Lopalco M, Antonelli F, De Cesaris M, Fogolari M, Dicuonzo G, Ciccozzi M. Susceptibility to measles in migrant population: implication for policy makers. Journal of travel medicine. 2018;25(1):tax080.\u003c/li\u003e\n \u003cli\u003eKibreab F, Lewycka S, Tewelde A. Impact of mother\u0026rsquo;s education on full immunization of children aged 12\u0026ndash;23 months in Eritrea: population and health survey 2010 data analysis. BMC Public Health. 2020;20:1-10.\u003c/li\u003e\n \u003cli\u003eGeremew TT, Gezie LD, Abejie AN. Geographical variation and associated factors of childhood measles vaccination in Ethiopia: a spatial and multilevel analysis. BMC public health. 2019;19:1-15.\u003c/li\u003e\n \u003cli\u003eTesfa GA, Demeke AD, Hailegebreal S, Amede ES, Ngusie HS, Kasie MN, Seboka BT. Spatial distribution and associated factors of measles vaccination among children aged 12\u0026ndash;23 months in Ethiopia. A spatial and multilevel analysis. Human Vaccines \u0026amp; Immunotherapeutics. 2022;18(1):2035558.\u003c/li\u003e\n \u003cli\u003eAltez MR. Appropriate/Measles Vaccination Is Key for Prevention of Subacute Sclerosing Panencephalitis. The Journal of Pediatrics. 2022;246:1-3.\u003c/li\u003e\n \u003cli\u003eHutchins SS, Papania MJ, Amler R, Maes EF, Grabowsky M, Bromberg K, Glasglow V, Speed T, Bellini WJ, Orenstein WA. Evaluation of the measles clinical case definition. J Infect Dis. 2004 May 1;189 Suppl 1:S153-9. eng. Epub 2004/04/24. doi:10.1086/379652. Cited in: Pubmed; PMID 15106104.\u003c/li\u003e\n \u003cli\u003e2021 WEBR. Consolidating Achievement of UHC in Eritrea. WHO. . 2021 4 May Available from: https://www.afro.who.int/sites/default/files/2022-07/Who%20Eritrea%20Bienniun%20Report%20WHO%202020%20-%202021_0.pdf.\u003c/li\u003e\n \u003cli\u003eSowe A, Njie M, Sowe D, Fofana S, Ceesay L, Camara Y, Tesfaye B, Bah S, Bah AK, Baldeh AK, Dampha BD, Baldeh SN, Touray A. Epidemiology of measles cases, vaccine effectiveness, and performance towards measles elimination in The Gambia. PLoS One. 2021;16(10):e0258961. eng. Epub 2021/10/22. doi:10.1371/journal.pone.0258961. Cited in: Pubmed; PMID 34673828.\u003c/li\u003e\n \u003cli\u003eSabahelzain MM, Moukhyer M, Bosma H, van den Borne B. Determinants of measles vaccine hesitancy among Sudanese parents in Khartoum State, Sudan: a cross-sectional study. Vaccines. 2022;10(1):6.\u003c/li\u003e\n \u003cli\u003eGirmay A, Dadi AF. Being unvaccinated and having a contact history increased the risk of measles infection during an outbreak: a finding from measles outbreak investigation in rural district of Ethiopia. BMC Infect Dis. 2019 Apr 25;19(1):345. eng. Epub 2019/04/27. doi:10.1186/s12879-019-3973-8. Cited in: Pubmed; PMID 31023269.\u003c/li\u003e\n \u003cli\u003eMokaya EN, Isaac Z, Anyuon NA. Measles outbreak investigation in Aweil East county, South Sudan. Pan Afr Med J. 2021;40:87. eng. Epub 2021/12/16. doi:10.11604/pamj.2021.40.87.28370. Cited in: Pubmed; PMID 34909076.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Measles, Surveillance, Vaccination, Epidemiology, Spatial inequality","lastPublishedDoi":"10.21203/rs.3.rs-2905015/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-2905015/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cb\u003eBackground\u003c/b\u003e\u003c/p\u003e \u003cp\u003eUnderstanding the incidence of laboratory-confirmed measles virus (MV) cases, related factors, and spatial inequalities in testing and surveillance is crucial to proving evidence-based decisions in measles prevention and control programs. In this analysis, our aim was to evaluate these factors in Eritrea.\u003c/p\u003e\u003cp\u003e\u003cb\u003eMethods\u003c/b\u003e\u003c/p\u003e \u003cp\u003eReviewed and analyzed a disease surveillance database from 2002 to 2020, used descriptive statistics and logistic regression, and calculated spatial variability and distribution of confirmed cases using ArcGIS Pro version 3.0.1 with a significance level of 5%.\u003c/p\u003e\u003cp\u003e\u003cb\u003eResults\u003c/b\u003e\u003c/p\u003e \u003cp\u003eThe median age (IQR) was 7 years (4\u0026ndash;14 years) and the minimum-maximum age was 1 month \u0026ndash; 97 years. In total, 9,111 suspected cases, 2,767 (1,431 (51.7%) females vs 1,336 (48.3%) males) were serologically tested. Among the 608 (21.9%) laboratory-confirmed cases, 534 (87.8%) were unvaccinated and 53 (9.92%) were \u0026lt;\u0026thinsp;1 year old. The crude incidence rate (CIR) for MV was 14/100,000 persons. The age-specific positivity rate per 100,000 suspected cases tested was 21.5 with individuals\u0026thinsp;\u0026gt;\u0026thinsp;30 years presenting the highest rates, 69.9/100,000. The probability of test positivity was associated with an increasing age at the beginning of the rash (5\u0026ndash;9 years: OR\u0026thinsp;=\u0026thinsp;0.7, 95%CI: 0.5\u0026ndash;0.9, p value\u0026thinsp;=\u0026thinsp;0.02) (10\u0026ndash;14 years: OR\u0026thinsp;=\u0026thinsp;1.6, 95%CI: 1.1\u0026ndash;2.2, p value\u0026thinsp;=\u0026thinsp;0.005) (15\u0026ndash;29 years: OR\u0026thinsp;=\u0026thinsp;7, 95%CI: 5.3\u0026ndash;9.2, p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.001) (\u0026thinsp;\u0026gt;\u0026thinsp;=\u0026thinsp;30: OR\u0026thinsp;=\u0026thinsp;16.7, 95%CI: 11.7\u0026ndash;24, p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.001); Address (Anseba: OR\u0026thinsp;=\u0026thinsp;2.3, 95%CI: 1.7\u0026ndash;3.1, p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.001) (Debub: OR\u0026thinsp;=\u0026thinsp;2.7, 95%CI: 1.9\u0026ndash;3.9, p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.001) (Gash-Barka: OR\u0026thinsp;=\u0026thinsp;15.4, 95%CI: 10.9\u0026ndash;21.7, p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.001) (Northern Red Sea: OR\u0026thinsp;=\u0026thinsp;11.8, 95%CI: 8.5\u0026ndash;16.2, p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.001) (Southern Red Sea: OR\u0026thinsp;=\u0026thinsp;14.4, 95% CI: 8.2\u0026ndash;25.2, p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.001); Health facility (Health centre: OR\u0026thinsp;=\u0026thinsp;2.5, 95%CI: 1.9\u0026ndash;3.4, p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.001) (Hospital: OR\u0026thinsp;=\u0026thinsp;6.8, 95%CI: 5.1\u0026ndash;9.1, p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.001); Vaccination status (Unvaccinated: OR\u0026thinsp;=\u0026thinsp;14.7, 95%CI: 11.4\u0026ndash;19.1, p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.001); and year of onset of rash (2015: OR\u0026thinsp;=\u0026thinsp;1.4, 95% CI: 1.1\u0026ndash;1.7, p-value\u0026thinsp;\u0026lt;\u0026thinsp;0.001). Interestingly, uptake of the measles vaccine (MCV) coverage was associated with a similar complement of factors.\u003c/p\u003e\u003cp\u003e\u003cb\u003eConclusion\u003c/b\u003e\u003c/p\u003e \u003cp\u003eThe study concludes that efforts to eliminate measles in Eritrea are hindered by disparities in vaccine coverage and surveillance, and low vaccination rates in neighboring countries. The paper suggests that regional microplanning could be an effective strategy to improve surveillance and management in hard-to-reach regions.\u003c/p\u003e","manuscriptTitle":"Epidemiology of confirmed measles virus cases, surveillance, incidence, and associated factors in Eritrea: 18-year retrospective analysis","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2023-05-09 20:19:11","doi":"10.21203/rs.3.rs-2905015/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"eb21351c-12aa-40a5-95fe-e9da8f28bddc","owner":[],"postedDate":"May 9th, 2023","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":21264302,"name":"Epidemiology"},{"id":21264303,"name":"General Microbiology"},{"id":21264304,"name":"Virology"}],"tags":[],"updatedAt":"2023-05-09T20:19:12+00:00","versionOfRecord":[],"versionCreatedAt":"2023-05-09 20:19:11","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-2905015","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-2905015","identity":"rs-2905015","version":["v1"]},"buildId":"FbvkV6FR0MCFSLy54lSbu","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}